{ "ProductData": { "ID": "CPS_000002", "ProductType": "Others", "BrandName": "A1C-3", "ProductNameAddition": "Tina-quant Hemoglobin A1c Gen.3", "RegulatoryDisclaimer1": "For in vitro diagnostic use.", "DisclaimerGroup1": "IVD", "RegulatoryDisclaimer2": null, "DisclaimerGroup2": null, "RegulatoryDisclaimer3": null, "SampleType": [ "Plasma", "Serum", "Urine", "CSF (Cerebrospinal fluid)" ], "LicenseDisclaimers": [ ], "RelatedLinks": "", "Clone": "", "ControlTissue": [ "" ], "ISOtypes": "", "Species": [ "" ], "StainLocalization": [ "" ], "ProductNameGlobal": "A1C-3" }, "ProductImageDetails": { "ImagePath": "https://pim-media.roche.com/Images/Article_05336180190_im_en.png", "ImageType": "Image main" }, "Product2Taxonomy": { "Product2TaxonomyReferences": [ { "StructureSystemIdentifier": "Product_Grouping", "StructureSystemName": "Product Grouping", "NodeID": "01-0380", "StructureNodeStatus": "Active", "NodeName": "cobas HbA1c" }, { "StructureSystemIdentifier": "OWP_Product_Types", "StructureSystemName": "Product Types", "NodeID": "20-000-00", "StructureNodeStatus": "Active", "NodeName": "Assays Reagents and Strips" }, { "StructureSystemIdentifier": "Lab_Type", "StructureSystemName": "Lab Types", "NodeID": "050-00", "StructureNodeStatus": "Active", "NodeName": "Core Lab" }, { "StructureSystemIdentifier": "Disease_Areas", "StructureSystemName": "Disease Areas", "NodeID": "27-00-00", "StructureNodeStatus": "Active", "NodeName": "Metabolic disease" }, { "StructureSystemIdentifier": "Product_Solutions", "StructureSystemName": "Product Solutions", "NodeID": "020", "StructureNodeStatus": "Active", "NodeName": "Clinical Chemistry" }, { "StructureSystemIdentifier": "Applications", "StructureSystemName": "Applications", "NodeID": "99-00-00", "StructureNodeStatus": "Inactive", "NodeName": "" }, { "StructureSystemIdentifier": "OWP_Techniques", "StructureSystemName": "Techniques", "NodeID": "999-00", "StructureNodeStatus": "Inactive", "NodeName": "" }, { "StructureSystemIdentifier": "OWP_Family", "StructureSystemName": "Product Families", "NodeID": "370", "StructureNodeStatus": "Active", "NodeName": "Tina-quant" }, { "StructureSystemIdentifier": "Disease_Areas", "StructureSystemName": "Disease Areas", "NodeID": "13-00-00", "StructureNodeStatus": "Active", "NodeName": "Diabetes" }, { "StructureSystemIdentifier": "Health_Topics", "StructureSystemName": "Health Topics", "NodeID": "12-00-00", "StructureNodeStatus": "Active", "NodeName": "Endocrinology" }, { "StructureSystemIdentifier": "Pathogens", "StructureSystemName": "Pathogens", "NodeID": "99-00-00", "StructureNodeStatus": "Inactive", "NodeName": "" }, { "StructureSystemIdentifier": "Indications", "StructureSystemName": "Indications", "NodeID": "102", "StructureNodeStatus": "Active", "NodeName": "Metabolic" }, { "StructureSystemIdentifier": "OWP_Family", "StructureSystemName": "Product Families", "NodeID": "622", "StructureNodeStatus": "Active", "NodeName": "COBAS INTEGRA" } ] }, "Product2Materials": { "P2MaterialReferences": [ { "MaterialNum": "05336180190", "MaterialDescription": "HbA1c TQ Gen.3, 200Tests,cobas c111", "RegisteredProductName": "A1C-3", "GTIN": "04015630926282", "ProductCategoryText": "Reagents, kits", "OldMaterialNumber": "", "PackSizePIM360": "2 × 100 tests", "PackSizeDescPIM360": "cobas c 111", "MaterialAnnotation": "", "ReadyForUse": "true", "OrderInformation": "" }, { "MaterialNum": "05336163190", "MaterialDescription": "HbA1c TQ Gen.3, 150Tests,cobas c501/INT", "RegisteredProductName": "A1C-3", "GTIN": "04015630926275", "ProductCategoryText": "Reagents, kits", "OldMaterialNumber": "", "PackSizePIM360": "150 tests", "PackSizeDescPIM360": "COBAS INTEGRA 400 Plus, cobas c 311/501/502", "MaterialAnnotation": "", "ReadyForUse": "true", "OrderInformation": "" } ] }, "Product2Products": { "Product2ProductReference": [ { "ProductID": "INS_2113", "BrandName": "cobas® c 502 module", "ProductNameAddition": "", "ReferenceType": "Instrument", "Classification": [ { "IdentifierofStructureSystem": "1", "NameofStructureSystem": "GPCH", "StructureNodeID": "2324", "StructureGroupPath": "ClinChem fully automated->Systems / Digital Products->cobas c systems->cobas c 502", "StructureGroupName": "cobas c 502", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Product_Types", "NameofStructureSystem": "Product Types", "StructureNodeID": "10-000-00", "StructureGroupPath": "Analyzer Instruments and Systems", "StructureGroupName": "Analyzer Instruments and Systems", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Lab_Type", "NameofStructureSystem": "Lab Types", "StructureNodeID": "050-00", "StructureGroupPath": "Core Lab", "StructureGroupName": "Core Lab", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Product_Solutions", "NameofStructureSystem": "Product Solutions", "StructureNodeID": "020", "StructureGroupPath": "Clinical Chemistry", "StructureGroupName": "Clinical Chemistry", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Applications", "NameofStructureSystem": "Applications", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "OWP_Techniques", "NameofStructureSystem": "Techniques", "StructureNodeID": "999-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Disease_Areas", "NameofStructureSystem": "Disease Areas", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Pathogens", "NameofStructureSystem": "Pathogens", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Health_Topics", "NameofStructureSystem": "Health Topics", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "OWP_Family", "NameofStructureSystem": "Product Families", "StructureNodeID": "614", "StructureGroupPath": "cobas c", "StructureGroupName": "cobas c", "StructureNodeStatus": "Active" } ] }, { "ProductID": "INS_2043", "BrandName": "cobas® c 311 analyzer", "ProductNameAddition": "", "ReferenceType": "Instrument", "Classification": [ { "IdentifierofStructureSystem": "1", "NameofStructureSystem": "GPCH", "StructureNodeID": "308", "StructureGroupPath": "ClinChem fully automated->Systems / Digital Products->cobas c systems->cobas c 311", "StructureGroupName": "cobas c 311", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Product_Types", "NameofStructureSystem": "Product Types", "StructureNodeID": "10-000-00", "StructureGroupPath": "Analyzer Instruments and Systems", "StructureGroupName": "Analyzer Instruments and Systems", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Lab_Type", "NameofStructureSystem": "Lab Types", "StructureNodeID": "050-00", "StructureGroupPath": "Core Lab", "StructureGroupName": "Core Lab", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Product_Solutions", "NameofStructureSystem": "Product Solutions", "StructureNodeID": "020", "StructureGroupPath": "Clinical Chemistry", "StructureGroupName": "Clinical Chemistry", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Applications", "NameofStructureSystem": "Applications", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "OWP_Techniques", "NameofStructureSystem": "Techniques", "StructureNodeID": "999-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Disease_Areas", "NameofStructureSystem": "Disease Areas", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Pathogens", "NameofStructureSystem": "Pathogens", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Health_Topics", "NameofStructureSystem": "Health Topics", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "OWP_Family", "NameofStructureSystem": "Product Families", "StructureNodeID": "614", "StructureGroupPath": "cobas c", "StructureGroupName": "cobas c", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Family", "NameofStructureSystem": "Product Families", "StructureNodeID": "560", "StructureGroupPath": "cobas 4000", "StructureGroupName": "cobas 4000", "StructureNodeStatus": "Active" } ] }, { "ProductID": "INS_526", "BrandName": "cobas® c 111 analyzer", "ProductNameAddition": "", "ReferenceType": "Instrument", "Classification": [ { "IdentifierofStructureSystem": "1", "NameofStructureSystem": "GPCH", "StructureNodeID": "307", "StructureGroupPath": "ClinChem fully automated->Systems / Digital Products->cobas c systems->cobas c 111", "StructureGroupName": "cobas c 111", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Product_Types", "NameofStructureSystem": "Product Types", "StructureNodeID": "10-000-00", "StructureGroupPath": "Analyzer Instruments and Systems", "StructureGroupName": "Analyzer Instruments and Systems", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Lab_Type", "NameofStructureSystem": "Lab Types", "StructureNodeID": "050-00", "StructureGroupPath": "Core Lab", "StructureGroupName": "Core Lab", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Lab_Type", "NameofStructureSystem": "Lab Types", "StructureNodeID": "110-00", "StructureGroupPath": "Point of Care Testing", "StructureGroupName": "Point of Care Testing", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Product_Solutions", "NameofStructureSystem": "Product Solutions", "StructureNodeID": "020", "StructureGroupPath": "Clinical Chemistry", "StructureGroupName": "Clinical Chemistry", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Applications", "NameofStructureSystem": "Applications", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "OWP_Techniques", "NameofStructureSystem": "Techniques", "StructureNodeID": "999-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Disease_Areas", "NameofStructureSystem": "Disease Areas", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Pathogens", "NameofStructureSystem": "Pathogens", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Health_Topics", "NameofStructureSystem": "Health Topics", "StructureNodeID": "11-00-00", "StructureGroupPath": "Critical Care", "StructureGroupName": "Critical Care", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Family", "NameofStructureSystem": "Product Families", "StructureNodeID": "614", "StructureGroupPath": "cobas c", "StructureGroupName": "cobas c", "StructureNodeStatus": "Active" } ] }, { "ProductID": "INS_338", "BrandName": "cobas® c 501 module", "ProductNameAddition": "", "ReferenceType": "Instrument", "Classification": [ { "IdentifierofStructureSystem": "1", "NameofStructureSystem": "GPCH", "StructureNodeID": "309", "StructureGroupPath": "ClinChem fully automated->Systems / Digital Products->cobas c systems->cobas c 501", "StructureGroupName": "cobas c 501", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Product_Types", "NameofStructureSystem": "Product Types", "StructureNodeID": "10-000-00", "StructureGroupPath": "Analyzer Instruments and Systems", "StructureGroupName": "Analyzer Instruments and Systems", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Lab_Type", "NameofStructureSystem": "Lab Types", "StructureNodeID": "050-00", "StructureGroupPath": "Core Lab", "StructureGroupName": "Core Lab", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Product_Solutions", "NameofStructureSystem": "Product Solutions", "StructureNodeID": "020", "StructureGroupPath": "Clinical Chemistry", "StructureGroupName": "Clinical Chemistry", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Applications", "NameofStructureSystem": "Applications", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "OWP_Techniques", "NameofStructureSystem": "Techniques", "StructureNodeID": "999-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Disease_Areas", "NameofStructureSystem": "Disease Areas", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Pathogens", "NameofStructureSystem": "Pathogens", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Health_Topics", "NameofStructureSystem": "Health Topics", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "OWP_Family", "NameofStructureSystem": "Product Families", "StructureNodeID": "614", "StructureGroupPath": "cobas c", "StructureGroupName": "cobas c", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Family", "NameofStructureSystem": "Product Families", "StructureNodeID": "679", "StructureGroupPath": "cobas 6000", "StructureGroupName": "cobas 6000", "StructureNodeStatus": "Active" } ] } ] }, "ProductSpec": [ { "ProductSpecVariant": { "MetaData": { "DocumentMaterialNumber": "05336996001", "ProductName": "A1C-3", "ProductLongName": "Tina-quant Hemoglobin A1c Gen.3 - Whole blood and Hemolysate Application", "Language": "en", "DocumentVersion": "3", "DocumentObjectID": "FF0000000463C80E", "DocumentOriginID": "FF00000001C6830E", "MaterialNumbers": [ "05336180190" ], "InstrumentReferences": [ { "ID": "307", "BrandName": "cobas c 111" } ], "DisclaimerText": "Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative." }, "Chapters": [ { "Name": "IntendedUse", "Value": "

Intended use

In vitro test for the quantitative determination of mmol/mol hemoglobin A1c (IFCC) and % hemoglobin A1c (DCCT/NGSP) in whole blood and hemolysates prepared from whole blood on the cobas c 111 system. HbA1c determinations are useful for monitoring of long-term blood glucose control in individuals with diabetes mellitus. Moreover, this test is to be used as an aid in diagnosis of diabetes and identifying patients who may be at risk for developing diabetes.

", "Language": "en" }, { "Name": "TestPrinciple", "Value": "

Test principle

Test principle
LREFZander R, Lang W, Wolf HU. Alkaline haematin D-575, a new tool for the determination of haemoglobin as an alternative to the cyanhaemiglobin method. I. Description of the method. Clin Chim Acta 1984;136:83-93.
,
LREFWolf HU, Lang W, Zander R. Alkaline haematin D-575, a new tool for the determination of haemoglobin as an alternative to the cyanhaemiglobin method. II. Standardization of the method using pure chlorohaemin. Clin Chim Acta 1984;136:95-104.
,
LREFLittle RR, Wiedmeyer HM, England JD, et al. Interlaboratory standardization of measurements of glycohemoglobins. Clin Chem 1992;38:2472-2478.

This method uses TTAB (Tetradecyltrimethylammonium bromide) as the detergent in the hemolyzing reagent to eliminate interference from leukocytes (TTAB does not lyse leukocytes). Sample pretreatment to remove labile HbA1c is not necessary.

All hemoglobin variants which are glycated at the β‑chain N‑terminus and which have antibody-recognizable regions identical to that of HbA1c are measured by this assay. Consequently, the metabolic state of patients having uremia or the most frequent hemoglobinopathies (HbAS, HbAC, HbAE) can be determined using this assay.

LREFFrank EL, Moulton L, Little RR, et al. Effects of hemoglobin C and S traits on seven glycated hemoglobin methods. Clin Chem 2000;46(6):864-867.
,
LREFChang J, Hoke C, Ettinger B, et al. Evaluation and Interference Study of Hemoglobin A1c Measured by Turbidimetric Inhibition Immunoassay. Am J Clin Pathol 1998;109(3):274-278.

Hemoglobin A1c
The HbA1c determination is based on the turbidimetric inhibition immunoassay (TINIA) for hemolyzed whole blood.

  • Sample and addition of R1 (buffer/antibody):
    Glycohemoglobin (HbA1c) in the sample reacts with anti-HbA1c antibody to form soluble antigen-antibody complexes. Since the specific HbA1c antibody site is present only once on the HbA1c molecule, complex formation does not take place.

  • Addition of SR (buffer/polyhapten) and start of reaction:
    The polyhaptens react with excess anti-HbA1c antibodies to form an insoluble antibody-polyhapten complex which can be measured turbidimetrically.

Hemoglobin
Liberated hemoglobin in the hemolyzed sample is converted to a derivative having a characteristic absorption spectrum which is measured bichromatically during the preincubation phase (sample + R1) of the above immunological reaction. A separate Hb reagent is consequently not necessary.
The final result is expressed as mmol/mol HbA1c or percent HbA1c and is calculated from the HbA1c/Hb ratio as follows:

Protocol 1 (mmol/mol HbA1c acc. to IFCC):
HbA1c (mmol/mol) = (HbA1c/Hb) × 1000

Protocol 2 (% HbA1c acc. to DCCT/NGSP):
HbA1c (%) = (HbA1c/Hb) × 91.5 + 2.15

", "Language": "en" }, { "Name": "MeasuringRange", "Value": "

Limits and ranges

Measuring range

Hb: 2.48‑24.8 mmol/L (4‑40 g/dL)
HbA1c: 0.186‑1.61 mmol/L (0.3‑2.6 g/dL)*

*The measuring range for HbA1c lies between 0.186 mmol/L and the concentration of the highest standard. The test range stated above is based on a typical calibrator value of 1.61 mmol/L.
This corresponds to a measuring range of 23‑196 mmol/mol HbA1c (IFCC) and 4.2‑20.1 % HbA1c (DCCT/NGSP) at a typical hemoglobin concentration of 8.2 mmol/L (13.2 g/dL).

In rare cases of \">test rng\" flags that might occur with the whole blood application remix the whole blood sample and repeat the analysis with the same settings.

Lower limits of measurement

Limit of Blank and Limit of Detection

Hb:

Limit of Blank

= 0.31 mmol/L (0.50 g/dL)

Limit of Detection

= 0.62 mmol/L (1.00 g/dL)

HbA1c:

Limit of Blank

= 0.12 mmol/L (0.19 g/dL)

Limit of Detection

= 0.18 mmol/L (0.29 g/dL)

The Limit of Blank and Limit of Detection were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17‑A requirements.

The Limit of Blank is the 95th percentile value from n ≥ 60 measurements of analyte‑free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte‑free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples.

The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

", "Language": "en" }, { "Name": "ExpectedValues", "Value": "

Expected values

Protocol 1 (mmol/mol HbA1c acc. to IFCC): 29‑42 mmol/mol HbA1c

LREFJunge,W, Wilke B, Halabi A, et al. Determination of reference levels in adults for hemoglobin A1c (HbA1c). Poster presentation EUROMEDLAB, Barcelona 2003.

Protocol 2 (% HbA1c acc. to DCCT/NGSP): 4.8‑5.9 % HbA1c

LREFJunge,W, Wilke B, Halabi A, et al. Determination of reference levels in adults for hemoglobin A1c (HbA1c). Poster presentation EUROMEDLAB, Barcelona 2003.

This reference range was obtained by measuring 482 well-characterized healthy individuals without diabetes mellitus. HbA1c levels higher than the upper end of this reference range are an indication of hyperglycemia during the preceding 2 to 3 months or longer. According to the recommendations of the American Diabetes Association values above 48 mmol/mol HbA1c (IFCC) or 6.5 % HbA1c (DCCT/NGSP) are suitable for the diagnosis of diabetes mellitus.

LREFInternational Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care 2009;32(7):1327-1334.
,
LREFDiagnosis and Classification of Diabetes Mellitus. Diabetes Care 2010;33(1):62-69.
Patients with HbA1c values in the range of 39‑46 mmol/mol HbA1c (IFCC) or 5.7‑6.4 % HbA1c (DCCT/NGSP) may be at a risk of developing diabetes.
LREFInternational Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care 2009;32(7):1327-1334.
,
LREFDiagnosis and Classification of Diabetes Mellitus. Diabetes Care 2010;33(1):62-69.

HbA1c levels may reach 195 mmol/mol HbA1c (IFCC) or 20 % HbA1c (DCCT/NGSP) and more in poorly controlled diabetes. Therapeutic action is suggested at levels above 64 mmol/mol HbA1c (IFCC) or 8 % HbA1c (DCCT/NGSP). Diabetes patients with HbA1c levels below 53 mmol/mol HbA1c (IFCC) or 7 % HbA1c (DCCT/NGSP) meet the goal of the American Diabetes Association.

LREFAmerican Diabetes Association. Standards of Medical Care for patients with diabetes mellitus. Diabetes Care [Suppl.] 1995;18(1):8-15.
,
LREFSacks BW, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002;48:436-472.

HbA1c levels below the established reference range may indicate recent episodes of hypoglycemia, the presence of Hb variants, or shortened lifetime of erythrocytes.

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

", "Language": "en" }, { "Name": "LimitationInterference", "Value": "

Limitations - interference

Limitations - interference
LREFFrank EL, Moulton L, Little RR, et al. Effects of hemoglobin C and S traits on seven glycated hemoglobin methods. Clin Chem 2000;46(6):864-867.
,
LREFChang J, Hoke C, Ettinger B, et al. Evaluation and Interference Study of Hemoglobin A1c Measured by Turbidimetric Inhibition Immunoassay. Am J Clin Pathol 1998;109(3):274-278.
,
LREFMartina WV, Martijn EG, van der Molen M, et al. β-N-terminal glycohemoglobins in subjects with common hemoglobinopathies: relation with fructosamine and mean erythrocyte age. Clin Chem 1993;39:2259-2265.
,
LREFWeykamp CW, Penders TJ, Muskiet FAJ, et al. Influence of hemoglobin variants and derivatives on glycohemoglobin determinations, as investigated by 102 laboratories using 16 methods. Clin Chem 1993;39:1717-1723.
,
LREFAmerican Diabetes Association. Standards of Medical Care for patients with diabetes mellitus. Diabetes Care [Suppl.] 1995;18(1):8-15.
,
LREFSacks BW, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002;48:436-472.
,
LREFGlick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
,
LREFMiedema K. Influence of hemoglobin variants on the determination of glycated hemoglobin. Klin Lab 1993;39:1029-1032.
,
LREFNiederau C, Coe A, Katayama Y. Interference of Non-glucose Adducts on the Determination of Glycated Hemoglobins. Klin Lab 1993;39:1015-1023.
,
LREFRohlfing C, Connolly J, England J, et al. Effect of Elevated Fetal Hemoglobin on HbA1c Measurements: Four Common Assay Methods compared to the IFCC Reference Method. Poster Abstract AACC Annual Meeting 2006, Chicago. Clin Chem 2006;52(6) Suppl A 108.

  1. For diagnostic purposes, mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP) should be used in conjunction with information from other diagnostic procedures and clinical evaluations.

  2. The test is designed only for accurate and precise measurement of mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP). The individual results for total Hb and HbA1c concentration should not be reported.

  3. As a matter of principle, care must be taken when interpreting any HbA1c result from patients with Hb variants. Abnormal hemoglobins might affect the half life of the red cells or the in vivo glycation rates. In these cases even analytically correct results do not reflect the same level of glycemic control that would be expected in patients with normal hemoglobin.

    LREFMiedema K. Influence of hemoglobin variants on the determination of glycated hemoglobin. Klin Lab 1993;39:1029-1032.

    Whenever it is suspected that the presence of an Hb variant (e.g. HbSS, HbCC, or HbSC) affects the correlation between the HbA1c value and glycemic control HbA1c must not be used for the diagnosis of diabetes mellitus.

  4. Any cause of shortened erythrocyte survival will reduce exposure of erythrocytes to glucose with a consequent decrease in mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP), even though the time-averaged blood glucose level may be elevated. Causes of shortened erythrocyte lifetime might be hemolytic anemia or other hemolytic diseases, homozygous sickle cell trait, pregnancy, recent significant or chronic blood loss, etc. Caution should be used when interpreting the HbA1c results from patients with these conditions. HbA1c must not be used for the diagnosis of diabetes mellitus in the presence of such conditions.

  5. Glycated HbF is not detected by the assay as it does not contain the glycated β-chain that characterizes HbA1c. However, HbF is measured in the total Hb assay and as a consequence, specimens containing high amounts of HbF (≥ 10 %) may result in lower than expected mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP).

    LREFChang J, Hoke C, Ettinger B, et al. Evaluation and Interference Study of Hemoglobin A1c Measured by Turbidimetric Inhibition Immunoassay. Am J Clin Pathol 1998;109(3):274-278.
    ,
    LREFRohlfing C, Connolly J, England J, et al. Effect of Elevated Fetal Hemoglobin on HbA1c Measurements: Four Common Assay Methods compared to the IFCC Reference Method. Poster Abstract AACC Annual Meeting 2006, Chicago. Clin Chem 2006;52(6) Suppl A 108.

  6. mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP) are not suitable for diagnosis of gestational diabetes.

    LREFInternational Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care 2009;32(7):1327-1334.

  7. In very rare cases of rapidly evolving type 1 diabetes the increase of HbA1c values might be delayed compared to the acute increase in glucose concentrations. In these conditions diabetes mellitus must be diagnosed based on plasma glucose concentrations and/or the typical clinical symptoms.

    LREFInternational Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care 2009;32(7):1327-1334.

Criterion: Recovery within ± 10 % of initial value.

Icterus: No significant interference up to a conjugated and unconjugated bilirubin concentration of 1026 μmol/L or 60 mg/dL.

Lipemia: No significant interference up to an Intralipid concentration of 600 mg/dL. There is poor correlation between the triglycerides concentration and turbidity.

Glycemia: No significant interference up to a glucose level of 55.5 mmol/L (1000 mg/dL). A fasting sample is not required.

Rheumatoid factors: No significant interference up to a rheumatoid factor level of 750 IU/mL.

Drugs: No interference was found at therapeutic concentrations using common drug panels.

LREFBreuer J. Report on the Symposium "Drug effects in Clinical Chemistry Methods". Eur J Clin Chem Clin Biochem 1996;34:385-386.
,
LREFSonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001;38:376-385.

Other: No cross reactions with HbA0, HbA1a, HbA1b, acetylated hemoglobin, carbamylated hemoglobin, glycated albumin and labile HbA1c were found for the anti-HbA1c antibodies used in this kit.

For diagnostic purposes, the results should always be assessed in conjunction with the patient’s medical history, clinical examination and other findings.

ACTION REQUIRED
Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on the cobas c 111 analyzer. For information about test combinations requiring special wash steps, please refer to the latest version of the carry-over evasion list found with the CLEAN Method Sheet and the operator’s manual for further instructions.
Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.

", "Language": "en" }, { "Name": "OrderInformation", "Value": "

OrderInformation_111 (CC Reagents - cobas + Integra)

Order information

Analyzer(s) on which kit(s) can be used

05336180 190

Tina-quant Hemoglobin A1c Gen.3 (2 × 100 tests)

cobas c 111

Materials required (but not provided):

04528417 190

C.f.a.s. HbA1c (3 × 2 mL)

Code 674

05479207 190

PreciControl HbA1c norm (4 × 1 mL)

Code 208

05912504 190

PreciControl HbA1c path (4 × 1 mL)

Code 209

05007232 190

Hemolyzing Reagent Gen.2 (8 × 6.3 mL)

Code 952

11488457 122

HbA1c Hemolyzing Reagent for Tina-quant HbA1c (1000 mL)

11930630 001

Chimneys

", "Language": "en" }, { "Name": "SystemInformation", "Value": "

System information

Whole Blood DCCT (%): ACN 891 A1W3D and ACN 871 HBW3D
Hemolysate DCCT (%): ACN 861 A1H3D and ACN 841 HBH3D
Whole Blood IFCC (mmol/mol): ACN 264 A1W3I and ACN 265 HBW3I
Hemolysate IFCC (mmol/mol): ACN 251 A1H3I and ACN 231 HBH3I

", "Language": "en" }, { "Name": "Handling", "Value": "

Reagent handling

Ready for use

Under conditions of extreme humidity, condensation may lead to a dilution of the reagent that affects the measurements. Hence under environmental conditions in which temperature and humidity are equal to, or in excess of 25 °C/80 %, 28 °C/70 %, 30 °C/60 % or 32 °C/55 % a chimney (Cat. No. 11930630 001) should be used to reduce the condensation rate. Place a white chimney in R1 and a black chimney in SR. The chimneys can be reused for reagent bottles within the same kit. However, to avoid contamination of the reagent with detergent or dilution of the reagent with water it is not permitted to wash the chimneys before reuse.

", "Language": "en" }, { "Name": "TestDefinition", "Value": "

Applications for Hb and HbA1c

Whole Blood applications for Hb and HbA1c

cobas c 111 test definition Hb (HBW3I or HBW3D)

Measuring mode

Absorbance

Abs. calculation mode

Endpoint

Reaction direction

Increase

Wavelength A/B

378/659 nm

Calc. first/last

6/16

Unit

mmol/L

Reaction mode

R1-S

Pipetting parameters

Hb

Diluent (H2O)

R1

120 µL

Sample

6 µL

0 µL

Total volume

126 µL

cobas c 111 test definition HbA1c (A1W3I or A1W3D)

Measuring mode

Absorbance

Abs. calculation mode

Endpoint

Reaction direction

Increase

Wavelength A/B

340/659 nm

Calc. first/last

16/34

Unit

mmol/L

Reaction mode

R1-S-SR

Pipetting parameters

HbA1c

Diluent (H2O)

R1

120 µL

Sample

6 µL

0 µL

SR

24 µL

0 µL

Total volume

150 µL

Hemolysate applications for Hb and HbA1c

cobas c 111 test definition Hb (HBH3I or HBH3D)

Measuring mode

Absorbance

Abs. calculation mode

Endpoint

Reaction direction

Increase

Wavelength A/B

378/659 nm

Calc. first/last

6/16

Unit

mmol/L

Reaction mode

R1-S

Pipetting parameters

Hb

Diluent (H2O)

R1

120 µL

Sample

6 µL

0 µL

Total volume

126 µL

cobas c 111 test definition HbA1c (A1H3I or A1H3D)

Measuring mode

Absorbance

Abs. calculation mode

Endpoint

Reaction direction

Increase

Wavelength A/B

340/659 nm

Calc. first/last

16/34

Unit

mmol/L

Reaction mode

R1-S-SR

Pipetting parameters

HbA1c

Diluent (H2O)

R1

120 µL

Sample

6 µL

0 µL

SR

24 µL

0 µL

Total volume

150 µL

", "Language": "en" }, { "Name": "StorageStability", "Value": "

Storage and stability

Reagent

Shelf life at 2‑8 °C:

See expiration date on reagent

On-board in use and refrigerated on the analyzer:

4 weeks

Hemolyzing Reagent Gen.2, Cat. No. 05007232190 (concentrated)

Shelf life at 2‑8 °C:

See expiration date on vial label

On-board in use and refrigerated on the analyzer:

5 days

When storing at temperatures under 3 °C, the reagent may become cloudy. This has no effect on the function of the reagent and is reversible at higher temperatures. It is therefore recommended to equilibrate the reagent at room temperature for approximately 10 minutes and mix thoroughly before use.

", "Language": "en" }, { "Name": "Calibration", "Value": "

Calibration

Hb

Calibrator

C.f.a.s. HbA1c

HbA1c

Calibrator

C.f.a.s. HbA1c

Calibration dilution ratio

1:1, 1:1.5, 1:2.1, 1:3, 1:6, 1:15, performed automatically by the instrument

Calibrator diluent

Hemolyzing Reagent Gen.2

Calibration frequency

Each lot, every 14 days, and as required following quality control procedures

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Traceability: This method has been standardized against the approved IFCC reference method for the measurement of HbA1c in human blood

LREFKobold U, Jeppsson JO, Duelffer T, et al. Candidate reference methods for hemoglobin A1c based on peptide mapping. Clin Chem 1997;43:1944-1951.
,
LREFJeppsson JO, Kobold U, Finke A, et al. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med 2002;40:78-89.
and can be transferred to results traceable to DCCT/NGSP by calculation.

Note

Enter the assigned lot-specific and application-specific value of the calibrator. Use the appropriate C.f.a.s. HbA1c calibrator only.
The cobas c 111 Hemolyzing Reagent Gen.2 (Cat. No. 05007232 190) needs to be available on the analyzer. Otherwise the calibration cannot be performed.

", "Language": "en" }, { "Name": "Limitations", "Value": "", "Language": "en" }, { "Name": "PerformanceData", "Value": "

Specific performance data

Representative performance data on the cobas c 111 analyzer are given below. Results obtained in individual laboratories may differ.

", "Language": "en" }, { "Name": "Precision", "Value": "

Precision

Repeatability and intermediate precision were determined using human samples and controls in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP5 requirements (2 aliquots per run, 2 runs per day, 21 days). The following results were obtained (data based on DCCT/NGSP values):

Whole Blood application

Repeatability

Mean
% HbA1c

SD
% HbA1c

CV
%

PreciControl HbA1c norm

5.63

0.04

0.7

PreciControl HbA1c path

10.7

0.06

0.6

Human sample 1

5.21

0.04

0.7

Human sample 2

6.22

0.04

0.7

Human sample 3

7.34

0.05

0.7

Human sample 4

8.44

0.05

0.6

Human sample 5

11.0

0.06

0.5

Intermediate precision

Mean
% HbA1c

SD
% HbA1c

CV
%

PreciControl HbA1c norm

5.63

0.08

1.5

PreciControl HbA1c path

10.7

0.10

0.9

Human sample 1

5.21

0.07

1.4

Human sample 2

6.22

0.07

1.1

Human sample 3

7.34

0.09

1.2

Human sample 4

8.44

0.09

1.1

Human sample 5

11.0

0.10

0.9

Hemolysate application

Repeatability

Mean
% HbA1c

SD
% HbA1c

CV
%

PreciControl HbA1c norm

5.76

0.06

1.0

PreciControl HbA1c path

10.5

0.06

0.6

Human sample 1

4.99

0.07

1.5

Human sample 2

6.42

0.08

1.3

Human sample 3

10.2

0.07

0.7

Human sample 4

7.44

0.07

0.9

Human sample 5

7.69

0.05

0.7

Intermediate precision

Mean
% HbA1c

SD
% HbA1c

CV
%

PreciControl HbA1c norm

5.76

0.12

2.1

PreciControl HbA1c path

10.5

0.19

1.8

Human sample 1

4.99

0.11

2.2

Human sample 2

6.42

0.16

2.5

Human sample 3

10.2

0.18

1.8

Human sample 4

7.44

0.14

1.9

Human sample 5

7.69

0.13

1.6

", "Language": "en" }, { "Name": "MethodComparison", "Value": "

Method comparison

Evaluation of method comparison data is according to former NGSP certification criteria. The mean difference between the two methods and the 95 % confidence intervals of the differences in the range from 4‑10 % (DCCT/NGSP) are given. 95 % of the differences between the values obtained for individual samples with both methods fall within the range defined by the lower and upper 95 % confidence intervals of the differences.

Whole Blood application:

% HbA1c (DCCT/NGSP) values for human blood samples obtained on a cobas c 111 analyzer using the Tina‑quant Hemoglobin A1c Gen.3 reagent with the whole blood application (y) were compared to those determined using the same reagent with the whole blood application on a COBAS INTEGRA 400 plus analyzer (x).

Sample size (n) = 57

Mean difference: 0.22 % HbA1c

Lower 95 % confidence interval of differences: −0.22 % HbA1c

Upper 95 % confidence interval of differences: 0.66 % HbA1c

The sample concentrations were between 4.86 % and 12.2 % HbA1c (DCCT/NGSP values).

Hemolysate application:

% HbA1c (DCCT/NGSP) values for human blood samples obtained on a cobas c 111 analyzer using the Tina‑quant Hemoglobin A1c Gen.3 reagent with the hemolysate application (y) were compared to those determined using the same reagent with the hemolysate application on a COBAS INTEGRA 400 plus analyzer (x).

Sample size (n) = 57

Mean difference: 0.19 % HbA1c

Lower 95 % confidence interval of differences: −0.16 % HbA1c

Upper 95 % confidence interval of differences: 0.54 % HbA1c

The sample concentrations were between 4.58 % and 11.8 % HbA1c (DCCT/NGSP values).

", "Language": "en" }, { "Name": "Summary", "Value": "

Summary

Summary
LREFGoldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care 1995;18:896-909.
,
LREFGoldstein DE, Little RR. More than you ever wanted to know (but need to know) about glycohemoglobin testing. Diabetes Care 1994;17:938-939.
,
LREFThe Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
,
LREFUK Prospective Diabetes Study (UKPDS) group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
,
LREFFinke A, Kobold U, Hoelzel W, et al. Preparation of a candidate primary reference material for the international standardization of HbA1c determinations. Clin Chem Lab Med 1998;36(5):299-308.
,
LREFGoldstein DE, Little RR, Wiedmeyer HM, et al. Glycated hemoglobin: methodologies and clinical applications. Clin Chem 1986;32:B64-B70.
,
LREFNathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008;31:1473-1478.
,
LREFBunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 1978;200:21-27.

Hemoglobin (Hb) consists of four protein subunits, each containing a heme moiety, and is the red-pigmented protein located in the erythrocytes. Its main function is to transport oxygen and carbon dioxide in blood. Each Hb molecule is able to bind four oxygen molecules. Hb consists of a variety of subfractions and derivatives. Among this heterogeneous group of hemoglobins HbA1c is one of the glycated hemoglobins, a subfraction formed by the attachment of various sugars to the Hb molecule. HbA1c is formed in two steps by the nonenzymatic reaction of glucose with the N‑terminal amino group of the β‑chain of normal adult Hb (HbA). The first step is reversible and yields labile HbA1c. This is rearranged to form stable HbA1c in a second reaction step.

In the erythrocytes, the relative amount of HbA converted to stable HbA1c increases with the average concentration of glucose in the blood. The conversion to stable HbA1c is limited by the erythrocyte’s life span of approximately 100 to 120 days. As a result, HbA1c reflects the average blood glucose level during the preceding 2 to 3 months. HbA1c is thus suitable to monitor long-term blood glucose control in individuals with diabetes mellitus. Glucose levels closer to the time of the assay have a greater influence on the HbA1c level.

LREFGoldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care 1995;18:896-909.

The approximate relationship between HbA1c and mean blood glucose values during the preceding 2 to 3 months was analyzed in several studies. A recent study obtained the following correlation:

IFCC standardization (recalculated acc. to ref. 8)

• Estimated average glucose [mmol/L] = 0.146 × HbA1c (mmol/mol) + 0.834

or

• Estimated average glucose [mg/dL] = 2.64 × HbA1c (mmol/mol) + 15.03

Standardization acc. to DCCT/NGSP

LREFNathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008;31:1473-1478.

• Estimated average glucose [mmol/L] = 1.59 × HbA1c (%) - 2.59

or

• Estimated average glucose [mg/dL] = 28.7 × HbA1c (%) - 46.7

The risk of diabetic complications, such as diabetic nephropathy and retinopathy, increases with poor metabolic control. In accordance with its function as an indicator for the mean blood glucose level, HbA1c predicts the development of diabetic complications in diabetes patients.

LREFThe Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
,
LREFUK Prospective Diabetes Study (UKPDS) group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.

For monitoring of long term glycemic control, testing every 3 to 4 months is generally sufficient. In certain clinical situations, such as gestational diabetes, or after a major change in therapy, it may be useful to measure HbA1c in 2 to 4 week intervals.

LREFGoldstein DE, Little RR, Wiedmeyer HM, et al. Glycated hemoglobin: methodologies and clinical applications. Clin Chem 1986;32:B64-B70.

", "Language": "en" }, { "Name": "Reagents", "Value": "

Reagents – working solutions

R1

Antibody reagent
MES

FREFMES = 2-morpholinoethane sulfonic acid
buffer: 0.025 mol/L; TRIS
FREFTRIS = Tris(hydroxymethyl)-aminomethane
buffer: 0.015 mol/L, pH 6.2; HbA1c antibody (ovine serum) ≥ 0.5 mg/mL; detergents; stabilizers; preservative

SR

Polyhapten reagent
MES buffer: 0.025 mol/L; TRIS buffer: 0.015 mol/L, pH 6.2; HbA1c polyhapten: ≥ 8 µg/mL; detergents; stabilizers; preservative

", "Language": "en" }, { "Name": "PrecautionsWarnings", "Value": "

Precautions and warnings

For in vitro diagnostic use for health care professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste:
Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards:
Apply all relevant local disposal regulations to determine the safe disposal.

Safety data sheet available for professional user on request.

This kit contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:

Warning

H317

May cause an allergic skin reaction.

Prevention:

P261

Avoid breathing dust/fume/gas/mist/vapours/spray.

P272

Contaminated work clothing should not be allowed out of the workplace.

P280

Wear protective gloves.

Response:

P333 + P313

If skin irritation or rash occurs: Get medical advice/attention.

P362 + P364

Take off contaminated clothing and wash it before reuse.

Disposal:

P501

Dispose of contents/container to an approved waste disposal plant.

Product safety labeling follows EU GHS guidance.

Contact phone: all countries: +49-621-7590

", "Language": "en" }, { "Name": "Caution", "Value": "", "Language": "en" }, { "Name": "QualityControl", "Value": "

Quality control

For quality control, use control materials as listed in the “Order information” section. In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory’s individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Note

HbA1c controls carry a declaration for HbA1c ratio only. No declarations for Hb and HbA1c concentrations are provided. HbA1c controls must be included in the cobas c 111 systems Quality Control Program. For the hemolysate test the HbA1c controls must be hemolysed manually before using them for the Quality Control Program. Assigned target values in mmol/mol HbA1c according to IFCC are not included in the control barcodes and must be entered by the customer manually.

", "Language": "en" }, { "Name": "SpecimenPreparation", "Value": "

Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable.
Anticoagulated venous or capillary blood or hemolysate
The only acceptable anticoagulants are Li‑Heparin, K2‑EDTA, K3‑EDTA, Fluoride/Na2‑EDTA, Na‑Heparin and Fluoride/potassium oxalate.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

See the limitations and interferences section for details about possible sample interferences.

Stability:

3 days at 15‑25 °C
7 days at 2‑8 °C
6 months at (‑15)‑(‑25) °C

The recovery of HbA1c ratio values from sedimented samples, especially in case of poorly controlled diabetic patients, may be slightly elevated. To minimize this effect samples may be gently mixed by inversion prior to analysis.

Freeze only once. Mix specimen thoroughly after thawing.

Whole blood application

Whole blood samples must be placed on the instrument in uncapped primary tubes and not in (micro) tubes.

Hemolysate application

Manual hemolysate preparation:

  1. Allow blood specimen and Hemolyzing Reagent for Tina‑quant HbA1c (Cat. No. 11488457122) to equilibrate at room temperature before use.

  2. Moderately mix the sample immediately prior to pipetting, to ensure homogeneous mixture of erythrocytes. Take care to avoid the formation of foam.

  3. Dilute the sample with Hemolyzing Reagent for Tina‑quant HbA1c in the ratio 1:101 (1+100) using one of the following pipetting schemes.

    Pipette into tubes:

    Hemolyzing Reagent for Tina-quant HbA1c: 500 µL
    Specimen (patient or control): 5 µL
    or
    Hemolyzing Reagent for Tina-quant HbA1c: 1000 µL
    Specimen (patient or control): 10 µL
    or
    Hemolyzing Reagent for Tina-quant HbA1c: 2000 µL
    Specimen (patient or control): 20 µL

  4. Mix using a vibration mixer or by gentle swirling.

  5. The hemolysate can be used after the solution has changed color from red to brownish-green (approximately 1‑2 min).

Stability of the hemolysate:

4 hours at 15‑25 °C
24 hours at 2‑8 °C
6 months at (‑15)‑(‑25) °C

", "Language": "en" } ] } }, { "ProductSpecVariant": { "MetaData": { "DocumentMaterialNumber": "0105336163190c501", "ProductName": "A1C-3", "ProductLongName": "Tina-quant Hemoglobin A1c Gen.3 - Hemolysate and Whole Blood Application", "Language": "en", "DocumentVersion": "12", "DocumentObjectID": "FF00000004682D0E", "DocumentOriginID": "FF000000000B220E", "MaterialNumbers": [ "05336163190" ], "InstrumentReferences": [ { "ID": "308", "BrandName": "cobas c 311" }, { "ID": "2324", "BrandName": "cobas c 502" }, { "ID": "309", "BrandName": "cobas c 501" } ], "DisclaimerText": "Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative." }, "Chapters": [ { "Name": "IntendedUse", "Value": "

Intended use

In vitro test for the quantitative determination of mmol/mol hemoglobin (IFCC) and % hemoglobin A1c (DCCT/NGSP) in whole blood or hemolysate on Roche/Hitachi cobas c systems. HbA1c determinations are useful monitoring of long-term blood glucose control in individuals with diabetes mellitus. Moreover, this test is to be used as an aid in diagnosis of diabetes and identifying patients who may be at risk for developing diabetes.

", "Language": "en" }, { "Name": "TestPrinciple", "Value": "

Test principle

Test principle
LREFZander R, Lang W, Wolf HU. Alkaline haematin D-575, a new tool for the determination of haemoglobin as an alternative to the cyanhaemiglobin method. I. Description of the method. Clin Chim Acta 1984;136:83-93.
,
LREFWolf HU, Lang W, Zander R. Alkaline haematin D-575, a new tool for the determination of haemoglobin as an alternative to the cyanhaemiglobin method. II. Standardization of the method using pure chlorohaemin. Clin Chim Acta 1984;136:95-104.
,
LREFLittle RR, Wiedmeyer HM, England JD, et al. Interlaboratory standardization of measurements of glycohemoglobins. Clin Chem 1992;38:2472-2478.

This method uses TTABa) as the detergent in the hemolyzing reagent to eliminate interference from leukocytes (TTAB does not lyse leukocytes). Sample pretreatment to remove labile HbA1c is not necessary.

All hemoglobin variants which are glycated at the β‑chain N‑terminus and which have antibody-recognizable regions identical to that of HbA1c are determined by this assay. Consequently, the metabolic state of patients having uremia or the most frequent hemoglobinopathies (HbAS, HbAC, HbAD, HbAE) can be determined using this assay.

LREFFrank EL, Moulton L, Little RR, et al. Effects of hemoglobin C and S traits on seven glycated hemoglobin methods. Clin Chem 2000;46(6):864-867.
,
LREFChang J, Hoke C, Ettinger B, et al. Evaluation and Interference Study of Hemoglobin A1c Measured by Turbidimetric Inhibition Immunoassay. Am J Clin Pathol 1998;109(3):274-278.
,
LREFJaisson S, Leroy N, Gillery P, et al. Evaluation of the analytical performances of the Cobas c513 analyser for HbA1c assay. Biochem Med 2018;28(3):030708

a) TTAB = Tetradecyltrimethylammonium bromide

Hemoglobin A1c

The HbA1c determination is based on the turbidimetric inhibition immunoassay (TINIA) for hemolyzed whole blood.

  • Sample and addition of R1 (buffer/antibody)

    Glycohemoglobin (HbA1c) in the sample reacts with anti-HbA1c antibody to form soluble antigen-antibody complexes. Since the specific HbA1c antibody site is present only once on the HbA1c molecule, formation of insoluble complexes does not take place.

  • Addition of R3 (buffer/polyhapten) and start of reaction:

    The polyhaptens react with excess anti-HbA1c antibodies to form an insoluble antibody-polyhapten complex which can be determined turbidimetrically.

Hemoglobin

Liberated hemoglobin in the hemolyzed sample is converted to a derivative having a characteristic absorption spectrum which is measured bichromatically during the preincubation phase (sample + R1) of the above immunological reaction. A separate Hb reagent is consequently not necessary.

The final result is expressed as mmol/mol HbA1c or % HbA1c and is calculated from the HbA1c/Hb ratio as follows:

Protocol 1 (mmol/mol HbA1c acc. to IFCC):

HbA1c (mmol/mol) = (HbA1c/Hb) × 1000

Protocol 2 (% HbA1c acc. to DCCT/NGSP):

HbA1c (%) = (HbA1c/Hb) × 91.5 + 2.15

", "Language": "en" }, { "Name": "MeasuringRange", "Value": "

Limits and ranges

Measuring range

Hemoglobin: 2.48‑24.8 mmol/L (4‑40 g/dL).

HbA1c: 0.186‑1.61 mmol/L (0.3‑2.6 g/dL)

This corresponds to a measuring range of 23‑196 mmol/mol HbA1c (IFCC) and 4.2‑20.1 % HbA1c (DCCT/NGSP) at a typical hemoglobin concentration of 8.2 mmol/L (13.2 g/dL).

In rare cases of “>Test” flags which might occur with the use of the whole blood application, remix the whole blood sample and repeat the analysis with the same settings.

It is recommended to switch the auto rerun function off.

Lower limits of measurement

Limit of Blank and Limit of Detection

Hemoglobin:

Limit of Blank = 0.31 mmol/L (0.50 g/dL)

Limit of Detection = 0.62 mmol/L (1.00 g/dL)

HbA1c:

Limit of Blank = 0.12 mmol/L (0.19 g/dL)

Limit of Detection = 0.18 mmol/L (0.29 g/dL)

The Limit of Blank and Limit of Detection were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17‑A requirements.

The Limit of Blank is the 95th percentile value from n ≥ 60 measurements of analyte‑free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte‑free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples.

The Limit of Detection corresponds to the sample concentration which leads with a probability of 95 % to a measurement result above the Limit of Blank.

", "Language": "en" }, { "Name": "ExpectedValues", "Value": "

Expected values

Protocol 1 (mmol/mol HbA1c acc. to IFCC): 29‑42 mmol/mol HbA1c

LREFJunge,W, Wilke B, Halabi A, et al. Determination of reference levels in adults for hemoglobin A1c (HbA1c). Poster presentation EUROMEDLAB, Barcelona 2003.

Protocol 2 (% HbA1c acc. to DCCT/NGSP): 4.8‑5.9 % HbA1c

LREFJunge,W, Wilke B, Halabi A, et al. Determination of reference levels in adults for hemoglobin A1c (HbA1c). Poster presentation EUROMEDLAB, Barcelona 2003.

This reference range was obtained by measuring 482 well-characterized healthy individuals without diabetes mellitus. HbA1c levels higher than the upper end of this reference range are an indication of hyperglycemia during the preceding 2 to 3 months or longer. According to the recommendations of the American Diabetes Association values above 48 mmol/mol HbA1c (IFCC) or 6.5 % HbA1c (DCCT/NGSP) are suitable for the diagnosis of diabetes mellitus.

LREFInternational Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care 2009;32(7):1327-1334.
,
LREFDiagnosis and Classification of Diabetes Mellitus. Diabetes Care 2010;33(1):62-69.
Patients with HbA1c values in the range of 39‑46 mmol/mol HbA1c (IFCC) or 5.7‑6.4 % HbA1c (DCCT/NGSP) may be at risk of developing diabetes.
LREFInternational Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care 2009;32(7):1327-1334.
,
LREFDiagnosis and Classification of Diabetes Mellitus. Diabetes Care 2010;33(1):62-69.

HbA1c levels may reach 195 mmol/mol (IFCC) or 20 % (DCCT/NGSP) or higher in poorly controlled diabetes. Therapeutic action is suggested at levels above 64 mmol/mol HbA1c (IFCC) or 8 % HbA1c (DCCT/NGSP). Diabetes patients with HbA1c levels below 53 mmol/mol (IFCC) or 7 % (DCCT/NGSP) meet the goal of the American Diabetes Association.

LREFSacks BW, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002;48:436-472.
,
LREFAmerican Diabetes Association. Standards of Medical Care for patients with diabetes mellitus. Diabetes Care [Suppl.] 1995;18(1):8-15.

HbA1c levels below the established reference range may indicate recent episodes of hypoglycemia, the presence of Hb variants, or shortened lifetime of erythrocytes.

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

", "Language": "en" }, { "Name": "LimitationInterference", "Value": "

Limitations – interference for Whole Blood and Hemolysate Application

Limitations – interference for Whole Blood and Hemolysate Application
LREFFrank EL, Moulton L, Little RR, et al. Effects of hemoglobin C and S traits on seven glycated hemoglobin methods. Clin Chem 2000;46(6):864-867.
,
LREFChang J, Hoke C, Ettinger B, et al. Evaluation and Interference Study of Hemoglobin A1c Measured by Turbidimetric Inhibition Immunoassay. Am J Clin Pathol 1998;109(3):274-278.
,
LREFMartina WV, Martijn EG, van der Molen M, et al. β-N-terminal glycohemoglobins in subjects with common hemoglobinopathies: relation with fructosamine and mean erythrocyte age. Clin Chem 1993;39:2259-2265.
,
LREFWeykamp CW, Penders TJ, Muskiet FAJ, et al. Influence of hemoglobin variants and derivatives on glycohemoglobin determinations, as investigated by 102 laboratories using 16 methods. Clin Chem 1993;39:1717-1723.
,
LREFAmerican Diabetes Association. Standards of Medical Care for patients with diabetes mellitus. Diabetes Care [Suppl.] 1995;18(1):8-15.
,
LREFSacks BW, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002;48:436-472.
,
LREFGlick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
,
LREFMiedema K. Influence of hemoglobin variants on the determination of glycated hemoglobin. Klin Lab 1993;39:1029-1032.
,
LREFNiederau C, Coe A, Katayama Y. Interference of Non-glucose Adducts on the Determination of Glycated Hemoglobins. Klin Lab 1993;39:1015-1023.
,
LREFRohlfing C, Connolly J, England J, et al. Effect of Elevated Fetal Hemoglobin on HbA1c Measurements: Four Common Assay Methods compared to the IFCC Reference Method. Poster Abstract AACC Annual Meeting 2006, Chicago. Clin Chem 2006;52(6) Suppl A 108.

1. For diagnostic purposes, mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP) should be used in conjunction with information from other diagnostic procedures and clinical evaluations.

2. The test is designed only for accurate and precise measurement of mmol/mol HbA1c (IFCC) and % HbA1c (DCCT/NGSP). The individual results for total Hb and HbA1c concentration should not be reported.

3. As a matter of principle, care must be taken when interpreting any HbA1c result from patients with Hb variants. Abnormal hemoglobins might affect the half life of the red cells or the in vivo glycation rates. In these cases even analytically correct results do not reflect the same level of glycemic control that would be expected in patients with normal hemoglobin.

LREFMiedema K. Influence of hemoglobin variants on the determination of glycated hemoglobin. Klin Lab 1993;39:1029-1032.
Whenever it is suspected that the presence of an Hb variant (e.g. HbSS, HbCC or HbSC) affects the correlation between the HbA1c value and glycemic control, HbA1c must not be used for the diagnosis of diabetes mellitus.

4. Any cause of shortened erythrocyte survival or decrease in mean erythrocyte age will reduce exposure of erythrocytes to glucose with a consequent decrease in mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP), even though the time-averaged blood glucose level may be elevated. Causes of shortened erythrocyte lifetime might be hemolytic anemia or other hemolytic diseases, homozygous sickle cell trait, pregnancy, recent significant or chronic blood loss, etc. Similarly, recent blood transfusions can alter the mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP).Caution should be used when interpreting the HbA1c results from patients with these conditions. HbA1c must not be used for the diagnosis of diabetes mellitus in the presence of such conditions.

5. Glycated HbF is not detected by the assay as it does not contain the glycated β‑chain that characterizes HbA1c. However, HbF is measured in the total Hb assay and as a consequence, specimens containing high amounts of HbF (> 10 %) may result in lower than expected mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP).

LREFChang J, Hoke C, Ettinger B, et al. Evaluation and Interference Study of Hemoglobin A1c Measured by Turbidimetric Inhibition Immunoassay. Am J Clin Pathol 1998;109(3):274-278.
,
LREFRohlfing C, Connolly J, England J, et al. Effect of Elevated Fetal Hemoglobin on HbA1c Measurements: Four Common Assay Methods compared to the IFCC Reference Method. Poster Abstract AACC Annual Meeting 2006, Chicago. Clin Chem 2006;52(6) Suppl A 108.

6. mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP) are not suitable for the diagnosis of gestational diabetes.

LREFInternational Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care 2009;32(7):1327-1334.

7. In very rare cases of rapidly evolving type 1 diabetes the increase of the HbA1c values might be delayed compared to the acute increase in glucose concentrations. In these conditions diabetes mellitus must be diagnosed based on plasma glucose concentrations and/or the typical clinical symptoms.

LREFInternational Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care 2009;32(7):1327-1334.

Criterion: Recovery within ± 10 % of initial value.

Icterus:

LREFGlick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
No significant interference up to an I index of 60 for conjugated and unconjugated bilirubin (approximate conjugated and unconjugated bilirubin concentration: 1026 µmol/L or 60 mg/dL).

Lipemia (Intralipid):

LREFGlick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
No significant interference up to an Intralipid concentration of 600 mg/dL. There is poor correlation between triglycerides concentration and turbidity.

Glycemia: No significant interference up to a glucose level of 55.5 mmol/L (1000 mg/dL). A fasting sample is not required.

Rheumatoid factors: No significant interference from rheumatoid factors up to a concentration of 750 IU/mL.

Drugs: No interference was found at therapeutic concentrations using common drug panels.

LREFBreuer J. Report on the Symposium "Drug effects in Clinical Chemistry Methods". Eur J Clin Chem Clin Biochem 1996;34:385-386.
,
LREFSonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001;38:376-385.

Other: No cross reactions with HbA0, HbA1a, HbA1b, acetylated hemoglobin, carbamylated hemoglobin, glycated albumin and labile HbA1c were found for the anti-HbA1c antibodies used in this kit.

For diagnostic purposes, the results should always be assessed in conjunction with the patient’s medical history, clinical examination and other findings.

ACTION REQUIRED
Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on cobas c systems. The latest version of the carry‑over evasion list can be found with the NaOHD-SMS-SmpCln1+2-SCCS Method Sheets. For further instructions refer to the operator’s manual. cobas c 502 analyzer: All special wash programming necessary for avoiding carry‑over is available via the cobas link, manual input is required in certain cases.

Where required, special wash/carry‑over evasion programming must be implemented prior to reporting results with this test.

", "Language": "en" }, { "Name": "OrderInformation", "Value": "

OrderInformation

Order information

Analyzer(s) on which cobas c pack(s) can be used

05336163 190

Tina-quant Hemoglobin A1c Gen.3 (150 tests)

System ID 07 7455 3

cobas c 311, cobas c 501/502

Materials required (but not provided):

04528417 190

Calibrator f.a.s. HbA1c (3 x 2 mL)

Code 674

05479207 190

PreciControl HbA1c norm (4 × 1 mL)

Code 208

05912504 190

PreciControl HbA1c path (4 × 1 mL)

Code 209

04528182 190

Hemolyzing Reagent Gen.2 (51 mL)*

System ID 07 6873 1

11488457 122

HbA1c Hemolyzing Reagent for Tina‑quant HbA1c (1000 mL)

For Hemolysate Application only

* The value encoded in the instrument settings is 45 mL to account for the dead volume of the bottles.

", "Language": "en" }, { "Name": "SystemInformation", "Value": "

System information

Whole Blood Application - Standardized according to IFCC transferable to DCCT/NGSP

HB-W3:

ACN 871

Hemoglobin (Hb)

A1-W3:

ACN 881

Hemoglobin A1c (HbA1c)

RWD3:

ACN 891

Ratio % HbA1c (acc. to DCCT/NGSP)

A1CD2:

ACN 952

Hemolyzing reagent

Hemolysate Application - Standardized according to IFCC transferable to DCCT/NGSP

HB-H3:

ACN 841

Hemoglobin (Hb)

A1–H3:

ACN 851

Hemoglobin A1c (HbA1c)

RHD3:

ACN 861

Ratio % HbA1c (acc. to DCCT/NGSP)

A1CD2:

ACN 952

Hemolyzing reagent

", "Language": "en" }, { "Name": "Handling", "Value": "

Reagent handling

Ready for use

", "Language": "en" }, { "Name": "TestDefinition", "Value": "

Test definition

Whole Blood application for Hb (HB‑W3) and HbA1c (A1‑W3)

cobas c 311 test definition Hb (HB-W3)

Assay type

1-Point

Reaction time / Assay points

10 / 23

Wavelength (sub/main)

660 / 376 nm

Reaction direction

Increase

Unit

mmol/L (g/dL)

Reagent pipetting

Diluent (H2O)

R1

120 μL

-

R3

24 μL

-

Sample volumes

Sample

Sample dilution

Sample

Diluent (Hemolyzing reagent)

Normal

5 μL

2 μL

180 μL

Decreased

5 μL

2 μL

180 μL

Increased

5 μL

2 μL

180 μL

cobas c 311 test definition HbA1c (A1-W3)

Assay type

2-Point End

Reaction time / Assay points

10 / 23‑57

Wavelength (sub/main)

660 / 340 nm

Reaction direction

Increase

Unit

mmol/L (g/dL)

Reagent pipetting

Diluent (H2O)

R1

120 μL

-

R3

24 μL

-

Sample volumes

Sample

Sample dilution

Sample

Diluent (Hemolyzing reagent)

Normal

5 μL

2 μL

180 μL

Decreased

5 μL

2 μL

180 μL

Increased

5 μL

2 μL

180 μL

cobas c 501/502 test definition Hb (HB-W3)

Assay type

1-Point

Reaction time / Assay points

10 / 34

Wavelength (sub/main)

660 / 376 nm

Reaction direction

Increase

Unit

mmol/L (g/dL)

Reagent pipetting

Diluent (H2O)

R1

120 μL

-

R3

24 μL

-

Sample volumes

Sample

Sample dilution

Sample

Diluent (Hemolyzing reagent)

Normal

5 μL

2 μL

180 μL

Decreased

5 μL

2 μL

180 μL

Increased

5 μL

2 μL

180 μL

cobas c 501/502 test definition HbA1c (A1-W3)

Assay type

2-Point End

Reaction time / Assay points

10 / 34-70

Wavelength (sub/main)

660 / 340 nm

Reaction direction

Increase

Unit

mmol/L (g/dL)

Reagent pipetting

Diluent (H2O)

R1

120 μL

-

R3

24 μL

-

Sample volumes

Sample

Sample dilution

Sample

Diluent (Hemolyzing reagent)

Normal

5 μL

2 μL

180 μL

Decreased

5 μL

2 μL

180 μL

Increased

5 μL

2 μL

180 μL

Ratio definition for mmol/mol HbA1c and % HbA1c calculation
Protocol 1 (mmol/mol HbA1c acc. to IFCC):

Abbreviated ratio name

RWI3

Equation

(A1-W3/HB-W3) × 1000

Unit

mmol/mol

Protocol 2 (% HbA1c acc. to DCCT/NGSP):

Abbreviated ratio name

RWD3 (891)

Equation

(A1-W3/HB-W3) × 91.5 + 2.15

Unit

%

Protocol 2 is already implemented in the application (ACN 891). The mmol/mol HbA1c values according to Protocol 1 (IFCC) must be manually calculated according to the above equation. If requested a calculated test with the formula in protocol 1 can be programmed under Utility > calculated test on the cobas c 311 analyzer and on the cobas c 501/502 analyzers. Please use the following settings:

Sample Type

Supernt.

Unit of Measure

mM/M

Report Name

HbA1c Gen.3 IFCC

Item

RWI3

Formula

(A1-W3/HB-W3) x 1000

The ratio for HbA1c (mmol/mol HbA1c acc. to IFCC and % HbA1c acc. to DCCT/NGSP) will be automatically calculated after result output of both tests. It is recommended to report % HbA1c values (DCCT/NGSP) to one decimal place and mmol/mol HbA1c values (IFCC) without decimal places, which can be entered in the editable field “expected values”.

Hemolysate Application for Hb (HB‑H3) and HbA1c (A1‑H3)

cobas c 311 test definition Hb (HB-H3)

Assay type

1-Point

Reaction time / Assay points

10 / 23

Wavelength (sub/main)

660 / 376 nm

Reaction direction

Increase

Unit

mmol/L (g/dL)

Reagent pipetting

Diluent (H2O)

R1

120 μL

-

R3

24 μL

-

Sample volumes

Sample

Sample dilution

Sample

Diluent (Hemolyzing reagent)

Normal

5 μL

-

-

Decreased

5 μL

-

-

Increased

5 μL

-

-

cobas c 311 test definition HbA1c (A1-H3)

Assay type

2-Point End

Reaction time / Assay points

10 / 23-57

Wavelength (sub/main)

660 / 340 nm

Reaction direction

Increase

Unit

mmol/L (g/dL)

Reagent pipetting

Diluent (H2O)

R1

120 μL

-

R3

24 μL

-

Sample volumes

Sample

Sample dilution

Sample

Diluent (Hemolyzing reagent)

Normal

5 μL

-

-

Decreased

5 μL

-

-

Increased

5 μL

-

-

cobas c 501/502 test definition Hb (HB-H3)

Assay type

1‑Point

Reaction time / Assay points

10 / 34

Wavelength (sub/main)

660 / 376 nm

Reaction direction

Increase

Unit

mmol/L (g/dL)

Reagent pipetting

Diluent (H2O)

R1

120 μL

-

R3

24 μL

-

Sample volumes

Sample

Sample dilution

Sample

Diluent (Hemolyzing reagent)

Normal

5 μL

-

-

Decreased

5 μL

-

-

Increased

5 μL

-

-

cobas c 501/502 test definition HbA1c (A1-H3)

Assay type

2‑Point End

Reaction time / Assay points

10 / 34-70

Wavelength (sub/main)

660 / 340 nm

Reaction direction

Increase

Unit

mmol/L (g/dL)

Reagent pipetting

Diluent (H2O)

R1

120 μL

-

R3

24 μL

-

Sample volumes

Sample

Sample dilution

Sample

Diluent (Hemolyzing reagent)

Normal

5 μL

-

-

Decreased

5 μL

-

-

Increased

5 μL

-

-

Ratio definition for HbA1c (mmol/mol (IFCC) or % (DCCT/NGSP)) calculation

Protocol 1 (mmol/mol HbA1c acc. to IFCC):

Abbreviated ratio name

RHI3

Equation

(A1-H3/HB-H3) x 1000

Unit

mmol/mol

Protocol 2 (% HbA1c acc. to DCCT/NGSP):

Abbreviated ratio name

RHD3 (861)

Equation

(A1-H3/HB-H3) x 91.5 + 2.15

Unit

%

Protocol 2 is already implemented in the application (ACN 861). The mmol/mol HbA1c values according to Protocol 1 (IFCC) must be manually calculated according to the above equation. If requested a calculated test with the formula in protocol 1 can be programmed under Utility > calculated test on the cobas c 311 analyzer and on the cobas c 501/502 analyzers. Please use the following settings:

Sample Type

Supernt.

Unit of Measure

mM/M

Report Name

HbA1c Gen.3 IFCC

Item

RHI3

Formula

(A1-H3/HB-H3) x 1000

The ratio for HbA1c (mmol/mol HbA1c acc. to IFCC and % HbA1c acc. to DCCT/NGSP) will be automatically calculated after result output of both tests. It is recommended to report % HbA1c values (DCCT/NGSP) to one decimal place and mmol/mol HbA1c values (IFCC) without decimal places, which can be entered in the editable field “expected values”.

", "Language": "en" }, { "Name": "StorageStability", "Value": "

Storage and stability

A1C-3

Shelf life at 2‑8 °C:

See expiration date on cobas c pack label.

On-board in use and refrigerated on the analyzer:

4 weeks

Hemolyzing reagent

Shelf life at 2‑8 °C:

See expiration date on cobas c pack label.

When storing at temperatures under 3 °C, the reagent may become cloudy. This has no effect on the function of the reagent and is reversible at higher temperatures. It is therefore recommended to equilibrate the reagent at room temperature for approximately 10 minutes and mix thoroughly before use.

On-board in use and refrigerated on the analyzer:

4 weeks

", "Language": "en" }, { "Name": "Calibration", "Value": "

Calibration

Calibration for Whole Blood and Hemolysate Application

Hb

Calibrators

S1-S2: C.f.a.s. HbA1c

Calibration mode

Linear

HbA1c

Calibrators

S1-S6: C.f.a.s. HbA1c

Calibration mode

Spline

Calibration frequency

Hb and HbA1c: full calibration is recommended

- after 29 days during shelf life

- after reagent lot change

- as required following quality control procedures

Always calibrate both assays (Hb and HbA1c) in parallel. Automatic calibration at QC failure should be deactivated.

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Traceability: This method has been standardized against the approved IFCC reference method for the measurement of HbA1c in human blood

LREFKobold U, Jeppsson JO, Duelffer T, et al. Candidate reference methods for hemoglobin A1c based on peptide mapping. Clin Chem 1997;43:1944-1951.
,
LREFJeppsson JO, Kobold U, Finke A, et al. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med 2002;40:78-89.
and can be transferred to results traceable to DCCT/NGSP by calculation.

Note for Whole Blood and Hemolysate Application

Enter the assigned lot-specific and application-specific value of the calibrator. Use the appropriate C.f.a.s. HbA1c calibrator only.

The cobas c Hemolyzing Reagent Gen.2 pack, 51 mL, Cat. No. 04528182 190, needs to be available on the analyzer otherwise the calibration cannot be performed.

", "Language": "en" }, { "Name": "Limitations", "Value": "", "Language": "en" }, { "Name": "PerformanceData", "Value": "

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

", "Language": "en" }, { "Name": "Precision", "Value": "

Precision

Precision was determined using human samples and controls in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP5 requirements with repeatability and intermediate precision (2 aliquots per run, 2 runs per day, 21 days). The following results were obtained (data based on DCCT/NGSP values):

Whole Blood Application:

Repeatability

Mean

% HbA1c

SD

%

CV

%

PreciControl HbA1c norm

5.3

0.07

1.3

PreciControl HbA1c path

9.9

0.11

1.1

Human sample 1

4.4

0.07

1.6

Human sample 2

5.6

0.09

1.6

Human sample 3

8.0

0.08

1.0

Human sample 4

10.6

0.11

1.1

Intermediate precision

Mean

% HbA1c

SD

%

CV

%

PreciControl HbA1c norm

5.3

0.08

1.4

PreciControl HbA1c path

9.9

0.15

1.5

Human sample 1

4.4

0.09

1.9

Human sample 2

5.6

0.11

2.0

Human sample 3

8.0

0.11

1.4

Human sample 4

10.6

0.16

1.5

Hemolysate Application:

Repeatability

Mean

% HbA1c

SD

%

CV

%

PreciControl HbA1c norm

5.1

0.07

1.3

PreciControl HbA1c path

10.2

0.10

1.0

Human sample 1

4.3

0.06

1.4

Human sample 2

5.6

0.07

1.2

Human sample 3

8.2

0.08

1.0

Human sample 4

10.9

0.11

1.0

Intermediate precision

Mean

% HbA1c

SD

%

CV

%

PreciControl HbA1c norm

5.1

0.11

2.2

PreciControl HbA1c path

10.2

0.21

2.0

Human sample 1

4.3

0.10

2.3

Human sample 2

5.6

0.09

1.6

Human sample 3

8.2

0.16

1.9

Human sample 4

10.9

0.22

2.0

The data obtained on cobas c 501 analyzer(s) are representative for cobas c 311 analyzer(s).

", "Language": "en" }, { "Name": "MethodComparison", "Value": "

Method comparison

Evaluation of method comparison data is according to NGSP certification criteria. The mean difference between the two methods and the 95 % confidence intervals of the differences in the range from 4‑10 % (DCCT/NGSP) are given. 95 % of the differences between the values obtained for individual samples with both methods fall within the range defined by the lower and upper 95 % confidence intervals of the differences.

Whole Blood Application:

% HbA1c (DCCT/NGSP) values for human blood samples obtained on a cobas c 501 analyzer using the Tina‑quant Hemoglobin A1c Gen.3 reagent with the whole blood application (y) were compared with those determined using the corresponding reagent with the hemolysate application on a COBAS INTEGRA 800 analyzer (x).

Sample size (n) = 80

Mean difference

0.07 % HbA1c

Lower 95 % confidence interval of differences

-0.27 % HbA1c

Upper 95 % confidence interval of differences

0.42 % HbA1c

The sample concentrations were between 4.7 % and 9.8 % (DCCT/NGSP values).

% HbA1c (DCCT/NGSP) values for human blood samples obtained on a cobas c 501 analyzer using the Tina‑quant Hemoglobin A1c Gen.3 reagent with the whole blood application (y) were compared with those determined using the Tina‑quant Hemoglobin A1c Gen.2 reagent with the whole blood application (x).

Sample size (n) = 82

Mean difference

0.07 % HbA1c

Lower 95 % confidence interval of differences

-0.50 % HbA1c

Upper 95 % confidence interval of differences

0.65 % HbA1c

The sample concentrations were between 5.0 % and 9.9 % (DCCT/NGSP values).

% HbA1c (DCCT/NGSP) values for human blood samples obtained on a cobas c 501 analyzer using the Tina‑quant Hemoglobin A1c Gen.3 reagent with the whole blood application (y) were compared with those determined using the Tina‑quant Hemoglobin A1c Gen.2 reagent with the hemolysate application on a COBAS INTEGRA 800 analyzer (x).

Sample size (n) = 80

Mean difference

-0.09 % HbA1c

Lower 95 % confidence interval of differences

-0.46 % HbA1c

Upper 95 % confidence interval of differences

0.28 % HbA1c

The sample concentrations were between 4.7 % and 9.8 % (DCCT/NGSP values).

Hemolysate Application:

% HbA1c (DCCT/NGSP) values for human blood samples obtained on a cobas c 501 analyzer using the Tina‑quant Hemoglobin A1c Gen.3 reagent with the whole blood application (y) were compared with those determined using the Tina‑quant Hemoglobin A1c Gen.2 reagent with the hemolysate application on a COBAS INTEGRA 800 analyzer (x).

Sample size (n) = 111

Mean difference

-0.19 % HbA1c

Lower 95 % confidence interval of differences

-0.52 % HbA1c

Upper 95 % confidence interval of differences

0.14 % HbA1c

The sample concentrations were between 4.6 % and 9.9 % (DCCT/NGSP values).

% HbA1c (DCCT/NGSP) values for human blood samples obtained on a cobas c 501 analyzer using the Tina‑quant Hemoglobin A1c Gen.3 reagent with the hemolysate application (y) were compared with those determined using the Tina‑quant Hemoglobin A1c Gen.2 reagent with the whole blood application (x).

Sample size (n) = 84

Mean difference

-0.06 % HbA1c

Lower 95 % confidence interval of differences

-0.53 % HbA1c

Upper 95 % confidence interval of differences

0.41 % HbA1c

The sample concentrations were between 5.5 % and 9.9 % (DCCT/NGSP values).

% HbA1c (DCCT/NGSP) values for human blood samples obtained on a cobas c 501 analyzer using the Tina‑quant Hemoglobin A1c Gen.3 reagent with the hemolysate application (y) were compared with those determined using the Tina‑quant Hemoglobin A1c Gen.2 reagent with the hemolysate application on a COBAS INTEGRA 800 analyzer (x).

Sample size (n) = 111

Mean difference

-0.35 % HbA1c

Lower 95 % confidence interval of differences

-0.68 % HbA1c

Upper 95 % confidence interval of differences

-0.02 % HbA1c

The sample concentrations were between 4.7 % and 9.9 % (DCCT/NGSP values).

% HbA1c (DCCT/NGSP) values for human blood samples obtained on a cobas c 501 analyzer using the Tina‑quant Hemoglobin A1c Gen.3 reagent with the hemolysate application (y) were compared with those determined using the Tina‑quant Hemoglobin A1c Gen.2 reagent with the hemolysate application (x).

Sample size (n) = 113

Mean difference

-0.10 % HbA1c

Lower 95 % confidence interval of differences

-0.49 % HbA1c

Upper 95 % confidence interval of differences

0.31 % HbA1c

The sample concentrations were between 4.8 % and 9.7 % (DCCT/NGSP values).

The data obtained on cobas c 501 analyzer(s) are representative for cobas c 311 analyzer(s).

", "Language": "en" }, { "Name": "Summary", "Value": "

Summary

Summary
LREFGoldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care 1995;18:896-909.
,
LREFGoldstein DE, Little RR. More than you ever wanted to know (but need to know) about glycohemoglobin testing. Diabetes Care 1994;17:938-939.
,
LREFThe Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
,
LREFUK Prospective Diabetes Study (UKPDS) group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
,
LREFFinke A, Kobold U, Hoelzel W, et al. Preparation of a candidate primary reference material for the international standardization of HbA1c determinations. Clin Chem Lab Med 1998;36(5):299-308.
,
LREFGoldstein DE, Little RR, Wiedmeyer HM, et al. Glycated hemoglobin: methodologies and clinical applications. Clin Chem 1986;32:B64-B70.
,
LREFNathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008;31:1473-1478.
,
LREFBunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 1978;200:21-27.

Hemoglobin (Hb) consists of four protein subunits, each containing a heme moiety, and is the red-pigmented protein located in the erythrocytes. Its main function is the transport of oxygen and carbon dioxide in blood. Each Hb molecule is able to bind four oxygen molecules. Hb consists of a variety of subfractions and derivatives. Among this heterogeneous group of hemoglobins HbA1c is one of the glycated hemoglobins, a subfraction formed by the attachment of various sugars to the Hb molecule. HbA1c is formed in two steps by the non-enzymatic reaction of glucose with the N‑terminal amino group of the β‑chain of normal adult Hb (HbA). The first step is reversible and yields labile HbA1c. This is rearranged to form stable HbA1c in a second reaction step.

In the erythrocytes, the relative amount of HbA converted to stable HbA1c increases with the average concentration of glucose in the blood. The conversion to stable HbA1c is limited by the erythrocyte's life span of approximately 100 to 120 days. As a result, HbA1c reflects the average blood glucose level during the preceding 2 to 3 months. HbA1c is thus suitable to monitor long-term blood glucose control in individuals with diabetes mellitus. Glucose levels closer to the time of the assay have a greater influence on the HbA1c level.

LREFGoldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care 1995;18:896-909.

The approximate relationship between HbA1c and mean blood glucose values during the preceding 2 to 3 months was analyzed in several studies. A recent study obtained the following correlation:

IFCC standardization (recalculated acc. to ref. 8)

• Estimated average glucose [mmol/L] = 0.146 x HbA1c (mmol/mol) + 0.834 or

• Estimated average glucose [mg/dL] = 2.64 x HbA1c (mmol/mol) + 15.03

Standardization acc. to DCCT/NGSP

LREFNathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008;31:1473-1478.

• Estimated average glucose [mmol/L] = 1.59 x HbA1c (%) - 2.59 or

• Estimated average glucose [mg/dL] = 28.7 x HbA1c (%) - 46.7

The risk of diabetic complications, such as diabetic nephropathy and retinopathy, increases with poor metabolic control. In accordance with its function as an indicator for the mean blood glucose level, HbA1c predicts the development of diabetic complications in diabetes patients.

LREFThe Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
,
LREFUK Prospective Diabetes Study (UKPDS) group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.

For monitoring long term glycemic control, testing every 3 to 4 months is generally sufficient. In certain clinical situations, such as gestational diabetes, or after a major change in therapy, it may be useful to measure HbA1c in 2 to 4 week intervals.

LREFGoldstein DE, Little RR, Wiedmeyer HM, et al. Glycated hemoglobin: methodologies and clinical applications. Clin Chem 1986;32:B64-B70.

", "Language": "en" }, { "Name": "Reagents", "Value": "

Reagents – working solutions

R1

Antibody Reagent

MES buffer: 0.025 mol/L; TRIS buffer: 0.015 mol/L, pH 6.2; HbA1c antibody (ovine serum): ≥ 0.5 mg/mL; detergent; stabilizers; preservatives

R3

Polyhapten Reagent

MES buffer: 0.025 mol/L; TRIS buffer: 0.015 mol/L, pH 6.2; HbA1c polyhapten: ≥ 8 µg/mL; detergent; stabilizers; preservatives

R1 is in position A and R3 is in position C. Position B contains H2O for technical reasons.

", "Language": "en" }, { "Name": "PrecautionsWarnings", "Value": "

Precautions and warnings

For in vitro diagnostic use for health care professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste:
Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards:
Apply all relevant local disposal regulations to determine the safe disposal.

Safety data sheet available for professional user on request.

This kit contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:

Warning

H317

May cause an allergic skin reaction.

Prevention:

P261

Avoid breathing dust/fume/gas/mist/vapours/spray.

P272

Contaminated work clothing should not be allowed out of the workplace.

P280

Wear protective gloves.

Response:

P333 + P313

If skin irritation or rash occurs: Get medical advice/attention.

P362 + P364

Take off contaminated clothing and wash it before reuse.

Disposal:

P501

Dispose of contents/container to an approved waste disposal plant.

Product safety labeling follows EU GHS guidance.

Contact phone: all countries: +49-621-7590

", "Language": "en" }, { "Name": "Caution", "Value": "", "Language": "en" }, { "Name": "QualityControl", "Value": "

Quality control

Quality control for Whole Blood and Hemolysate Application

For quality control, use control materials as listed in the \"Order information\" section.

In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory’s individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

", "Language": "en" }, { "Name": "SpecimenPreparation", "Value": "

Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable.

Anticoagulated venous or capillary blood or hemolysate.

The only acceptable anticoagulants are Li‑heparin, K2‑EDTA, K3‑EDTA, Fluoride/Na2‑EDTA, Na‑Heparin and Fluoride/potassium oxalate.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

See the limitations and interferences section for details about possible sample interferences.

Stability:

3 days at 15‑25 °C

7 days at 2‑8 °C

6 months at (-15)‑(-25) °C

Freeze only once. Mix specimen thoroughly after thawing.

Hemolysate preparation for Hemolysate Application

1. Allow blood specimen and Hemolyzing Reagent for Tina‑quant  HbA1c to equilibrate at room temperature before use.

2. Moderately mix the sample immediately prior to pipetting to ensure a homogeneous mixture of erythrocytes. Take care to avoid the formation of foam.

3. Dilute the sample with Hemolyzing Reagent for Tina‑quant HbA1c (Cat. No. 11488457 122) in the ratio 1:101 (1+100) using one of the following pipetting schemes.

Pipette into tubes:

HbA1c Hemolyzing Reagent for Tina‑quant HbA1c

500 µL

1000 µL

2000 µL

Specimen (patient or control)

5 µL

10 µL

20 µL

4. Mix using a vibration mixer or by gentle swirling.

5. The hemolysate can be used after the solution has changed color from red to brownish-green (approx. 1‑2 min).

Stability of the hemolysate:

4 hours at 15‑25 °C

24 hours at 2‑8 °C

6 months at (-15)‑(-25) °C

", "Language": "en" } ] } }, { "ProductSpecVariant": { "MetaData": { "DocumentMaterialNumber": "0205336163190c501", "ProductName": "A1C-3", "ProductLongName": "Tina-quant Hemoglobin A1c Gen.3 - Hemolysate and Whole Blood Application", "Language": "en", "DocumentVersion": "7", "DocumentObjectID": "FF0000000239360E", "DocumentOriginID": "FF00000000CEAB0E", "MaterialNumbers": [ "05336163190" ], "InstrumentReferences": [ { "ID": "308", "BrandName": "cobas c 311" }, { "ID": "2324", "BrandName": "cobas c 502" }, { "ID": "309", "BrandName": "cobas c 501" } ], "DisclaimerText": "Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative." }, "Chapters": [ { "Name": "IntendedUse", "Value": "

Intended use

In vitro test for the quantitative determination of mmol/mol hemoglobin A1c (IFCC) and % hemoglobin A1c (DCCT/NGSP) in whole blood or in hemolysate on Roche/Hitachi cobas c systems.

", "Language": "en" }, { "Name": "TestPrinciple", "Value": "

Test principle

Test principle
LREFZander R, Lang W, Wolf HU. Alkaline haematin D-575, a new tool for the determination of haemoglobin as an alternative to the cyanhaemiglobin method. I. Description of the method. Clin Chim Acta 1984;136:83-93.
,
LREFWolf HU, Lang W, Zander R. Alkaline haematin D-575, a new tool for the determination of haemoglobin as an alternative to the cyanhaemiglobin method. II. Standardization of the method using pure chlorohaemin. Clin Chim Acta 1984;136:95-104.
,
LREFLittle RR, Wiedmeyer HM, England JD, et al. Interlaboratory standardization of measurements of glycohemoglobins. Clin Chem 1992;38:2472-2478.

This method uses TTABa) as the detergent in the hemolyzing reagent to eliminate interference from leukocytes (TTAB does not lyse leukocytes). Sample pretreatment to remove labile HbA1c is not necessary.

All hemoglobin variants which are glycated at the β‑chain N‑terminus and which have antibody-recognizable regions identical to that of HbA1c are determined by this assay. Consequently, the metabolic state of patients having uremia or the most frequent hemoglobinopathies (HbAS, HbAC, HbAE) can be determined using this assay.

LREFFrank EL, Moulton L, Little RR, et al. Effects of hemoglobin C and S traits on seven glycated hemoglobin methods. Clin Chem 2000;46(6):864-867.
,
LREFChang J, Hoke C, Ettinger B, et al. Evaluation and Interference Study of Hemoglobin A1c Measured by Turbidimetric Inhibition Immunoassay. Am J Clin Pathol 1998;109(3):274-278.

a) TTAB = Tetradecyltrimethylammonium bromide

Hemoglobin A1c

The HbA1c determination is based on the turbidimetric inhibition immunoassay (TINIA) for hemolyzed whole blood.

  • Sample and addition of R1 (buffer/antibody)

    Glycohemoglobin (HbA1c) in the sample reacts with anti-HbA1c antibody to form soluble antigen-antibody complexes. Since the specific HbA1c antibody site is present only once on the HbA1c molecule, formation of insoluble complexes does not take place.

  • Addition of R3 (buffer/polyhapten) and start of reaction:

    The polyhaptens react with excess anti-HbA1c antibodies to form an insoluble antibody-polyhapten complex which can be determined turbidimetrically.

Hemoglobin

Liberated hemoglobin in the hemolyzed sample is converted to a derivative having a characteristic absorption spectrum which is measured bichromatically during the preincubation phase (sample + R1) of the above immunological reaction. A separate Hb reagent is consequently not necessary.

The final result is expressed as mmol/mol HbA1c or % HbA1c and is calculated from the HbA1c/Hb ratio as follows:

Protocol 1 (mmol/mol HbA1c acc. to IFCC):

HbA1c (mmol/mol) = (HbA1c/Hb) × 1000

Protocol 2 (% HbA1c acc. to DCCT/NGSP):

LREFHoelzel W, Weykamp C, Jeppsson JO, et al. IFCC Reference System for measurement of hemoglobin A1c in human blood and the National Standardization Schemes in the United States, Japan, and Sweden: a method comparison study. Clin Chem 2004;50:166-174.

HbA1c (%) = (HbA1c/Hb) × 91.5 + 2.15

", "Language": "en" }, { "Name": "MeasuringRange", "Value": "

Limits and ranges

Measuring range

Hemoglobin: 2.48‑24.8 mmol/L (4‑40 g/dL).

HbA1c: 0.186‑1.61 mmol/L (0.3‑2.6 g/dL)

This corresponds to a measuring range of 23‑196 mmol/mol HbA1c (IFCC) and 4.2‑20.1 % HbA1c (DCCT/NGSP) at a typical hemoglobin concentration of 8.2 mmol/L (13.2 g/dL).

In rare cases of “>Test” flags which might occur with the use of the whole blood application, remix the whole blood sample and repeat the analysis with the same settings.

It is recommended to switch the auto rerun function off.

Lower limits of measurement

Limit of Blank and Limit of Detection

Hemoglobin:

Limit of Blank = 0.31 mmol/L (0.50 g/dL)

Limit of Detection = 0.62 mmol/L (1.00 g/dL)

HbA1c:

Limit of Blank = 0.12 mmol/L (0.19 g/dL)

Limit of Detection = 0.18 mmol/L (0.29 g/dL)

The Limit of Blank and Limit of Detection were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17‑A requirements.

The Limit of Blank is the 95th percentile value from n ≥ 60 measurements of analyte‑free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte‑free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples.

The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

", "Language": "en" }, { "Name": "ExpectedValues", "Value": "

Expected values

Protocol 1 (mmol/mol HbA1c acc. to IFCC):
20‑42 mmol/mol HbA1c

LREFParnes B, Niebauer L, Holcomb S, et al. Provider Deferred Decisions on Hemoglobin A1c Report from the Colorado Research Network (CaR) the High Plains Research Network (HPRN). J Am Fam Med 2006;19(1):20-23.
,
LREFAmerican Diabetes Association Position Statement. Test of Glycemia in Diabetes. Diabetes Care 2004;27(Suppl 1):91-93.
,
LREFLittle RR, Rohlfing C, Wiedmeyer HM, et al. The National Glycohemoglobin Standardization Program (NGSP): a five year progress report. Clin Chem 2001;47:1985-1992.
,
LREFRohlfing CL, Wiedmeyer HM, Little RR, et al. Defining the relationship between plasma glucose and HbA1c:analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 2002;25:275-278.

Protocol 2 (% HbA1c acc. to DCCT/NGSP): 4.0‑6.0 % HbA1c

HbA1c levels above the established reference range are an indication of hyperglycemia during the preceding 2 to 3 months or longer.

HbA1c levels may reach 195 mmol/mol (IFCC) or 20 % (DCCT/NGSP) or higher in poorly controlled diabetes. Therapeutic action is suggested at levels above 64 mmol/mol HbA1c (IFCC) or 8 % HbA1c (DCCT/NGSP). Diabetes patients with HbA1c levels below 53 mmol/mol HbA1c (IFCC) or 7 % HbA1c (DCCT/NGSP) meet the goal of the American Diabetes Association.

LREFAmerican Diabetes Association. Standards of Medical Care for patients with diabetes mellitus. Diabetes Care [Suppl.] 1995;18(1):8-15.

HbA1c levels below the established reference range may indicate recent episodes of hypoglycemia, the presence of Hb variants, or shortened lifetime of erythrocytes.

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

", "Language": "en" }, { "Name": "LimitationInterference", "Value": "

Limitations – interference for Whole Blood and Hemolysate Application

Limitations – interference for Whole Blood and Hemolysate Application
LREFFrank EL, Moulton L, Little RR, et al. Effects of hemoglobin C and S traits on seven glycated hemoglobin methods. Clin Chem 2000;46(6):864-867.
,
LREFChang J, Hoke C, Ettinger B, et al. Evaluation and Interference Study of Hemoglobin A1c Measured by Turbidimetric Inhibition Immunoassay. Am J Clin Pathol 1998;109(3):274-278.
,
LREFMartina WV, Martijn EG, van der Molen M, et al. β-N-terminal glycohemoglobins in subjects with common hemoglobinopathies: relation with fructosamine and mean erythrocyte age. Clin Chem 1993;39:2259-2265.
,
LREFWeykamp CW, Penders TJ, Muskiet FAJ, et al. Influence of hemoglobin variants and derivatives on glycohemoglobin determinations, as investigated by 102 laboratories using 16 methods. Clin Chem 1993;39:1717-1723.
,
LREFAmerican Diabetes Association. Standards of Medical Care for patients with diabetes mellitus. Diabetes Care [Suppl.] 1995;18(1):8-15.
,
LREFSacks BW, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002;48:436-472.
,
LREFGlick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
,
LREFMiedema K. Influence of hemoglobin variants on the determination of glycated hemoglobin. Klin Lab 1993;39:1029-1032.
,
LREFNiederau C, Coe A, Katayama Y. Interference of Non-glucose Adducts on the Determination of Glycated Hemoglobins. Klin Lab 1993;39:1015-1023.
,
LREFRohlfing C, Connolly S, England J, et al. Effect of elevated fetal hemoglobin on HbA1c measurements: four common assay methods compared to the IFCC reference method. Clin Chem 2006;52 Suppl 6:A108.

  1. For diagnostic purposes, mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP) should be used in conjunction with information from other diagnostic procedures and clinical evaluations.

  2. The test is designed only for accurate and precise measurement of mmol/mol HbA1c (IFCC) and % HbA1c (DCCT/NGSP). The individual results for total Hb and HbA1c concentration should not be reported.

  3. The test is not intended for the diagnosis of diabetes mellitus or for judging day-to-day glucose control and should not be used to replace daily home testing of urine or blood glucose.

  4. As a matter of principle, care must be taken when interpreting any HbA1c result from patients with Hb variants. Abnormal hemoglobins might affect the half life of the red cells or the in vivo glycation rates. In these cases even analytically correct results do not reflect the same level of glycemic control that would be expected in patients with normal hemoglobin.

    LREFMiedema K. Influence of hemoglobin variants on the determination of glycated hemoglobin. Klin Lab 1993;39:1029-1032.

  5. Any cause of shortened erythrocyte survival will reduce exposure of erythrocytes to glucose with a consequent decrease in mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP), even though the time-averaged blood glucose level may be elevated. Causes of shortened erythrocyte lifetime might be hemolytic anemia or other hemolytic diseases, homozygous sickle cell trait, pregnancy, recent significant or chronic blood loss, etc. Caution should be used when interpreting the HbA1c results from patients with these conditions.

  6. Glycated HbF is not detected as it does not contain the glycated β‑chain that characterizes HbA1c. However, HbF is measured in the Total Hb assay and as a consequence, specimens containing high amounts of HbF (> 10 %) may result in lower than expected mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP).

    LREFChang J, Hoke C, Ettinger B, et al. Evaluation and Interference Study of Hemoglobin A1c Measured by Turbidimetric Inhibition Immunoassay. Am J Clin Pathol 1998;109(3):274-278.
    ,
    LREFRohlfing C, Connolly S, England J, et al. Effect of elevated fetal hemoglobin on HbA1c measurements: four common assay methods compared to the IFCC reference method. Clin Chem 2006;52 Suppl 6:A108.

Criterion: Recovery within ± 10 % of initial value.

Icterus:

LREFGlick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
No significant interference up to an I index of 60 for conjugated and unconjugated bilirubin (approximate conjugated and unconjugated bilirubin concentration: 1026 µmol/L or 60 mg/dL).

Lipemia (Intralipid):

LREFGlick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
No significant interference up to an Intralipid concentration of 600 mg/dL. There is poor correlation between triglycerides concentration and turbidity.

Glycemia: No significant interference from glucose up to a concentration of 55.5 mmol/L (1000 mg/dL). A fasting sample is not required.

Rheumatoid factors: No significant interference from rheumatoid factor up to a concentration of 750 IU/mL.

Drugs: No interference was found at therapeutic concentrations using common drug panels.

LREFBreuer J. Report on the Symposium "Drug effects in Clinical Chemistry Methods". Eur J Clin Chem Clin Biochem 1996;34:385-386.
,
LREFSonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001;38:376-385.

Other: No cross reactions with HbA0, HbA1a, HbA1b, acetylated hemoglobin, glycated albumin and labile HbA1c were found for the anti-HbA1c antibodies used in this kit.

For diagnostic purposes, the results should always be assessed in conjunction with the patient’s medical history, clinical examination and other findings.

ACTION REQUIRED
Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on Roche/Hitachi cobas c systems. The latest version of the carry‑over evasion list can be found with the NaOHD-SMS-SmpCln1+2-SCCS Method Sheets. For further instructions refer to the operator’s manual. cobas c 502 analyzer: All special wash programming necessary for avoiding carry‑over is available via the cobas link, manual input is required in certain cases.

Where required, special wash/carry‑over evasion programming must be implemented prior to reporting results with this test.

", "Language": "en" }, { "Name": "OrderInformation", "Value": "

OrderInformation

Order information

Analyzer(s) on which cobas c pack(s) can be used

05336163 190

Tina-quant Hemoglobin A1c Gen.3 (150 tests)

System ID 07 7455 3

Roche/Hitachi cobas c 311, cobas c 501/502

04528417 190

C.f.a.s. HbA1c (3 x 2 mL)

Code 674

05479207 190

PreciControl HbA1c norm (4 × 1 mL)

Code 208

05912504 190

PreciControl HbA1c path (4 × 1 mL)

Code 209

04528182 190

Hemolyzing Reagent Gen.2 (51 mL)*

System ID 07 6873 1

11488457 122

HbA1c Hemolyzing Reagent for Tina‑quant HbA1c (1000 mL)

For Hemolysate Application only

* The value encoded in the instrument settings is 45 mL to account for the dead volume of the bottles.

", "Language": "en" }, { "Name": "SystemInformation", "Value": "

System information

Whole Blood Application - Standardized according to IFCC
transferable to DCCT/NGSP

HB-W3:

ACN 871

Hemoglobin (Hb)

A1-W3:

ACN 881

Hemoglobin A1c (HbA1c)

RWD3:

ACN 891

Ratio % HbA1c (acc. to DCCT/NGSP)

A1CD2:

ACN 952

Hemolyzing reagent

Hemolysate Application - Standardized according to IFCC transferable to DCCT/NGSP

HB-H3:

ACN 841

Hemoglobin (Hb)

A1–H3:

ACN 851

Hemoglobin A1c (HbA1c)

RHD3:

ACN 861

Ratio % HbA1c (acc. to DCCT/NGSP)

A1CD2:

ACN 952

Hemolyzing reagent

", "Language": "en" }, { "Name": "Handling", "Value": "

Reagent handling

Ready for use

", "Language": "en" }, { "Name": "TestDefinition", "Value": "

Test definition

Whole Blood application for Hb (HB‑W3) and HbA1c (A1‑W3)

cobas c 311 test definition Hb (HB-W3)

Assay type

1-Point

Reaction time / Assay points

10 / 23

Wavelength (sub/main)

660 / 376 nm

Reaction direction

Increase

Unit

mmol/L (g/dL)

Reagent pipetting

Diluent (H2O)

R1

120 μL

-

R3

24 μL

-

Sample volumes

Sample

Sample dilution

Sample

Diluent (Hemolyzing reagent)

Normal

5 μL

2 μL

180 μL

Decreased

5 μL

2 μL

180 μL

Increased

5 μL

2 μL

180 μL

cobas c 311 test definition HbA1c (A1-W3)

Assay type

2-Point End

Reaction time / Assay points

10 / 23‑57

Wavelength (sub/main)

660 / 340 nm

Reaction direction

Increase

Unit

mmol/L (g/dL)

Reagent pipetting

Diluent (H2O)

R1

120 μL

-

R3

24 μL

-

Sample volumes

Sample

Sample dilution

Sample

Diluent (Hemolyzing reagent)

Normal

5 μL

2 μL

180 μL

Decreased

5 μL

2 μL

180 μL

Increased

5 μL

2 μL

180 μL

cobas c 501/502 test definition Hb (HB-W3)

Assay type

1-Point

Reaction time / Assay points

10 / 34

Wavelength (sub/main)

660 / 376 nm

Reaction direction

Increase

Unit

mmol/L (g/dL)

Reagent pipetting

Diluent (H2O)

R1

120 μL

-

R3

24 μL

-

Sample volumes

Sample

Sample dilution

Sample

Diluent (Hemolyzing reagent)

Normal

5 μL

2 μL

180 μL

Decreased

5 μL

2 μL

180 μL

Increased

5 μL

2 μL

180 μL

cobas c 501/502 test definition HbA1c (A1-W3)

Assay type

2-Point End

Reaction time / Assay points

10 / 34-70

Wavelength (sub/main)

660 / 340 nm

Reaction direction

Increase

Unit

mmol/L (g/dL)

Reagent pipetting

Diluent (H2O)

R1

120 μL

-

R3

24 μL

-

Sample volumes

Sample

Sample dilution

Sample

Diluent (Hemolyzing reagent)

Normal

5 μL

2 μL

180 μL

Decreased

5 μL

2 μL

180 μL

Increased

5 μL

2 μL

180 μL

Ratio definition for mmol/mol HbA1c and % HbA1c calculation
Protocol 1 (mmol/mol HbA1c acc. to IFCC):

Abbreviated ratio name

RWI3

Equation

(A1-W3/HB-W3) × 1000

Unit

mmol/mol

Protocol 2 (% HbA1c acc. to DCCT/NGSP):

LREFHoelzel W, Weykamp C, Jeppsson JO, et al. IFCC Reference System for measurement of hemoglobin A1c in human blood and the National Standardization Schemes in the United States, Japan, and Sweden: a method comparison study. Clin Chem 2004;50:166-174.

Abbreviated ratio name

RWD3 (891)

Equation

(A1-W3/HB-W3) × 91.5 + 2.15

Unit

%

Protocol 2 is already implemented in the application (ACN 891). The mmol/mol HbA1c values according to Protocol 1 (IFCC) must be manually calculated according to the above equation. If requested a calculated test with the formula in Protocol 1 can be programmed under Utility > calculated test on the Roche/Hitachi cobas c 311 analyzer and on the Roche/Hitachi cobas c 501/502 analyzers. Please use the following settings:

Sample Type

Supernt.

Unit of Measure

mM/M

Report Name

HbA1c Gen.3 IFCC

Item

RWI3

Formula

(A1-W3/HB-W3) x 1000

The ratio for HbA1c (mmol/mol HbA1c acc. to IFCC and % HbA1c acc. to DCCT/NGSP) will be automatically calculated after result output of both tests. It is recommended to report % HbA1c values (DCCT/NGSP) to one decimal place and mmol/mol HbA1c values (IFCC) without decimal places, which can be entered in the editable field “expected values”.

Hemolysate Application for Hb (HB‑H3) and HbA1c (A1‑H3)

cobas c 311 test definition Hb (HB-H3)

Assay type

1-Point

Reaction time / Assay points

10 / 23

Wavelength (sub/main)

660 / 376 nm

Reaction direction

Increase

Unit

mmol/L (g/dL)

Reagent pipetting

Diluent (H2O)

R1

120 μL

-

R3

24 μL

-

Sample volumes

Sample

Sample dilution

Sample

Diluent

Normal

5 μL

-

-

Decreased

5 μL

-

-

Increased

5 μL

-

-

cobas c 311 test definition HbA1c (A1-H3)

Assay type

2-Point End

Reaction time / Assay points

10 / 23-57

Wavelength (sub/main)

660 / 340 nm

Reaction direction

Increase

Unit

mmol/L (g/dL)

Reagent pipetting

Diluent (H2O)

R1

120 μL

-

R3

24 μL

-

Sample volumes

Sample

Sample dilution

Sample

Diluent

Normal

5 μL

-

-

Decreased

5 μL

-

-

Increased

5 μL

-

-

cobas c 501/502 test definition Hb (HB-H3)

Assay type

1‑Point

Reaction time / Assay points

10 / 34

Wavelength (sub/main)

660 / 376 nm

Reaction direction

Increase

Unit

mmol/L (g/dL)

Reagent pipetting

Diluent (H2O)

R1

120 μL

-

R3

24 μL

-

Sample volumes

Sample

Sample dilution

Sample

Diluent

Normal

5 μL

-

-

Decreased

5 μL

-

-

Increased

5 μL

-

-

cobas c 501/502 test definition HbA1c (A1-H3)

Assay type

2‑Point End

Reaction time / Assay points

10 / 34-70

Wavelength (sub/main)

660 / 340 nm

Reaction direction

Increase

Unit

mmol/L (g/dL)

Reagent pipetting

Diluent (H2O)

R1

120 μL

-

R3

24 μL

-

Sample volumes

Sample

Sample dilution

Sample

Diluent

Normal

5 μL

-

-

Decreased

5 μL

-

-

Increased

5 μL

-

-

Ratio definition for HbA1c (mmol/mol (IFCC) or % (DCCT/NGSP))
calculation

Protocol 1 (mmol/mol HbA1c acc. to IFCC):

Abbreviated ratio name

RHI3

Equation

(A1-H3/HB-H3) x 1000

Unit

mmol/mol

Protocol 2 (% HbA1c acc. to DCCT/NGSP):

LREFHoelzel W, Weykamp C, Jeppsson JO, et al. IFCC Reference System for measurement of hemoglobin A1c in human blood and the National Standardization Schemes in the United States, Japan, and Sweden: a method comparison study. Clin Chem 2004;50:166-174.

Abbreviated ratio name

RHD3 (861)

Equation

(A1-H3/HB-H3) x 91.5 + 2.15

Unit

%

Protocol 2 is already implemented in the application (ACN 861). The mmol/mol HbA1c values according to Protocol 1 (IFCC) must be manually calculated according to the above equation. If requested a calculated test with the formula in Protocol 1 can be programmed under Utility > calculated test on the Roche/Hitachi cobas c 311 analyzer and on the Roche/Hitachi cobas c 501/502 analyzers. Please use the following settings:

Sample Type

Supernt.

Unit of Measure

mM/M

Report Name

HbA1c Gen.3 IFCC

Item

RHI3

Formula

(A1-H3/HB-H3) x 1000

The ratio for HbA1c (mmol/mol HbA1c acc. to IFCC and % HbA1c acc. to DCCT/NGSP) will be automatically calculated after result output of both tests. It is recommended to report % HbA1c values (DCCT/NGSP) to one decimal place and mmol/mol HbA1c values (IFCC) without decimal places, which can be entered in the editable field “expected values”.

", "Language": "en" }, { "Name": "StorageStability", "Value": "

Storage and stability

A1C-3

Shelf life at 2‑8 °C:

See expiration date on cobas c pack label.

On-board in use and refrigerated on the analyzer:

4 weeks

Hemolyzing reagent

Shelf life at 2‑8 °C:

See expiration date on cobas c pack label.

When storing at temperatures under 3 °C, the reagent may become cloudy. This has no effect on the function of the reagent and is reversible at higher temperatures. It is therefore recommended to equilibrate the reagent at room temperature for approximately 10 minutes and mix thoroughly before use.

On-board in use and refrigerated on the analyzer:

4 weeks

", "Language": "en" }, { "Name": "Calibration", "Value": "

Calibration

Calibration for Whole Blood and Hemolysate Application

Hb

Calibrators

S1-S2: C.f.a.s. HbA1c

Calibration mode

Linear

HbA1c

Calibrators

S1-S6: C.f.a.s. HbA1c

Calibration mode

Spline

Calibration frequency

Hb and HbA1c: full calibration is recommended

- after 29 days during shelf life

- after reagent lot change

- as required following quality control procedures

Always calibrate both assays (Hb and HbA1c) in parallel. Automatic calibration at QC failure should be deactivated.

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Traceability: This method has been standardized against the approved IFCC reference method for the measurement of HbA1c in human blood

LREFKobold U, Jeppsson JO, Duelffer T, et al. Candidate reference methods for hemoglobin A1c based on peptide mapping. Clin Chem 1997;43:1944-1951.
,
LREFJeppsson JO, Kobold U, Finke A, et al. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med 2002;40:78-89.
and can be transferred to results traceable to DCCT/NGSP by calculation.
LREFHoelzel W, Weykamp C, Jeppsson JO, et al. IFCC Reference System for measurement of hemoglobin A1c in human blood and the National Standardization Schemes in the United States, Japan, and Sweden: a method comparison study. Clin Chem 2004;50:166-174.

Note for Whole Blood and Hemolysate Application

Enter the assigned lot-specific and application-specific value of the calibrator. Use the appropriate C.f.a.s. HbA1c calibrator only.

The cobas c Hemolyzing Reagent Gen.2 pack, 51 mL, Cat. No. 04528182190, needs to be available on the analyzer otherwise the calibration cannot be performed.

", "Language": "en" }, { "Name": "Limitations", "Value": "", "Language": "en" }, { "Name": "PerformanceData", "Value": "

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

", "Language": "en" }, { "Name": "Precision", "Value": "

Precision

Precision was determined using human samples and controls in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP5 requirements with repeatability (n = 21) and intermediate precision (2 aliquots per run, 2 runs per day, 21 days). The following results were obtained (data based on DCCT/NGSP values):

Whole Blood Application:

Repeatability

Mean
% HbA1c

SD
% HbA1c

CV
%

PreciControl HbA1c norm

5.3

0.07

1.3

PreciControl HbA1c path

9.9

0.11

1.1

Human sample 1

4.4

0.07

1.6

Human sample 2

5.6

0.09

1.6

Human sample 3

8.0

0.08

1.0

Human sample 4

10.6

0.11

1.1

Intermediate precision

Mean
% HbA1c

SD
% HbA1c

CV
%

PreciControl HbA1c norm

5.3

0.08

1.4

PreciControl HbA1c path

9.9

0.15

1.5

Human sample 1

4.4

0.09

1.9

Human sample 2

5.6

0.11

2.0

Human sample 3

8.0

0.11

1.4

Human sample 4

10.6

0.16

1.5

Hemolysate Application:

Repeatability

Mean
% HbA1c

SD
% HbA1c

CV
%

PreciControl HbA1c norm

5.1

0.07

1.3

PreciControl HbA1c path

10.2

0.10

1.0

Human sample 1

4.3

0.06

1.4

Human sample 2

5.6

0.07

1.2

Human sample 3

8.2

0.08

1.0

Human sample 4

10.9

0.11

1.0

Intermediate precision

Mean
% HbA1c

SD
% HbA1c

CV
%

PreciControl HbA1c norm

5.1

0.11

2.2

PreciControl HbA1c path

10.2

0.21

2.0

Human sample 1

4.3

0.10

2.3

Human sample 2

5.6

0.09

1.6

Human sample 3

8.2

0.16

1.9

Human sample 4

10.9

0.22

2.0

", "Language": "en" }, { "Name": "MethodComparison", "Value": "

Method comparison

Evaluation of method comparison data is according to NGSP certification criteria. The mean difference between the two methods and the 95 % confidence intervals of the differences in the range from 4‑10 % (DCCT/NGSP) are given. 95 % of the differences between the values obtained for individual samples with both methods fall within the range defined by the lower and upper 95 % confidence intervals of the differences.

Whole Blood Application:

% HbA1c (DCCT/NGSP) values for human blood samples obtained on a Roche/Hitachi cobas c 501 analyzer using the Tina‑quant Hemoglobin A1c Gen.3 reagent with the whole blood application (y) were compared with those determined using the same reagent with the hemolysate application on a COBAS INTEGRA 800 analyzer (x).

Sample size (n) = 80

Mean difference

0.07 % HbA1c

Lower 95 % confidence interval of differences

-0.27 % HbA1c

Upper 95 % confidence interval of differences

0.42 % HbA1c

The sample concentrations were between 4.7 % and 9.8 % (DCCT/NGSP values).

% HbA1c (DCCT/NGSP) values for human blood samples obtained on a Roche/Hitachi cobas c 501 analyzer using the Tina‑quant Hemoglobin A1c Gen.3 reagent with the whole blood application (y) were compared with those determined using the Tina‑quant Hemoglobin A1c Gen.2 reagent with the whole blood application (x).

Sample size (n) = 82

Mean difference

0.07 % HbA1c

Lower 95 % confidence interval of differences

-0.50 % HbA1c

Upper 95 % confidence interval of differences

0.65 % HbA1c

The sample concentrations were between 5.0 % and 9.9 % (DCCT/NGSP values).

% HbA1c (DCCT/NGSP) values for human blood samples obtained on a Roche/Hitachi cobas c 501 analyzer using the Tina‑quant Hemoglobin A1c Gen.3 reagent with the whole blood application (y) were compared with those determined using the Tina‑quant Hemoglobin A1c Gen.2 reagent with the hemolysate application on a COBAS INTEGRA 800 analyzer (x).

Sample size (n) = 80

Mean difference

-0.09 % HbA1c

Lower 95 % confidence interval of differences

-0.46 % HbA1c

Upper 95 % confidence interval of differences

0.28 % HbA1c

The sample concentrations were between 4.7 % and 9.8 % (DCCT/NGSP values).

Hemolysate Application:

% HbA1c (DCCT/NGSP) values for human blood samples obtained on a Roche/Hitachi cobas c 501 analyzer using the Tina‑quant Hemoglobin A1c Gen.3 reagent with the hemolysate application (y) were compared with those determined using the Tina‑quant Hemoglobin A1c Gen.2 reagent with the hemolysate application on a COBAS INTEGRA 800 analyzer (x).

Sample size (n) = 111

Mean difference

-0.19 % HbA1c

Lower 95 % confidence interval of differences

-0.52 % HbA1c

Upper 95 % confidence interval of differences

0.14 % HbA1c

The sample concentrations were between 4.6 % and 9.9 % (DCCT/NGSP values).

% HbA1c (DCCT/NGSP) values for human blood samples obtained on a Roche/Hitachi cobas c 501 analyzer using the Tina‑quant Hemoglobin A1c Gen.3 reagent with the hemolysate application (y) were compared with those determined using the Tina‑quant Hemoglobin A1c Gen.2 reagent with the whole blood application (x).

Sample size (n) = 84

Mean difference

-0.06 % HbA1c

Lower 95 % confidence interval of differences

-0.53 % HbA1c

Upper 95 % confidence interval of differences

0.41 % HbA1c

The sample concentrations were between 5.0 % and 9.9 % (DCCT/NGSP values).

% HbA1c (DCCT/NGSP) values for human blood samples obtained on a Roche/Hitachi cobas c 501 analyzer using the Tina‑quant Hemoglobin A1c Gen.3 reagent with the hemolysate application (y) were compared with those determined using the Tina‑quant Hemoglobin A1c Gen.2 reagent with the hemolysate application on a COBAS INTEGRA 800 analyzer (x).

Sample size (n) = 111

Mean difference

-0.35 % HbA1c

Lower 95 % confidence interval of differences

-0.68 % HbA1c

Upper 95 % confidence interval of differences

-0.02 % HbA1c

The sample concentrations were between 4.7 % and 9.9 % (DCCT/NGSP values).

% HbA1c (DCCT/NGSP) values for human blood samples obtained on a Roche/Hitachi cobas c 501 analyzer using the Tina‑quant Hemoglobin A1c Gen.3 reagent with the hemolysate application (y) were compared with those determined using the Tina‑quant Hemoglobin A1c Gen.2 reagent with the hemolysate application (x).

Sample size (n) = 113

Mean difference

-0.10 % HbA1c

Lower 95 % confidence interval of differences

-0.49 % HbA1c

Upper 95 % confidence interval of differences

0.31 % HbA1c

The sample concentrations were between 4.8 % and 9.7 % (DCCT/NGSP values).

", "Language": "en" }, { "Name": "Summary", "Value": "

Summary

Summary
LREFGoldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care 1995;18:896-909.
,
LREFGoldstein DE, Little RR. More than you ever wanted to know (but need to know) about glycohemoglobin testing. Diabetes Care 1994;17:938-939.
,
LREFThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.
,
LREFSantiago JV. Lessons from the diabetes control and complications trial. Diabetes 1993;42:1549-1554.
,
LREFIntensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
,
LREFFlückiger R, Mortensen HB. Review: glycated haemoglobins. J Chromatogr 1988;429:279-292.
,
LREFGoldstein DE, Little RR, Wiedmeyer HM, et al. Glycated hemoglobin: methodologies and clinical applications. Clin Chem 1986;32:B64-B70.
,
LREFBunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 1978;200:21-27.

Hemoglobin (Hb) consists of four protein subunits, each containing a heme moiety, and is the red-pigmented protein located in the erythrocytes. Its main function is to transport oxygen and carbon dioxide in blood. Each Hb molecule is able to bind four oxygen molecules. Hb consists of a variety of subfractions and derivatives. Among this heterogeneous group of hemoglobins HbA1c is one of the glycated hemoglobins, a subfraction formed by the attachment of various sugars to the Hb molecule. HbA1c is formed in two steps by the nonenzymatic reaction of glucose with the N‑terminal amino group of the β‑chain of normal adult Hb (HbA). The first step is reversible and yields labile HbA1c. This is rearranged to form stable HbA1c in a second reaction step.

In the erythrocytes, the relative amount of HbA converted to stable HbA1c increases with the average concentration of glucose in the blood. The conversion to stable HbA1c is limited by the erythrocyte's life span of approximately 100 to 120 days. As a result, HbA1c reflects the average blood glucose level during the preceding 2 to 3 months. HbA1c is thus suitable to monitor long-term blood glucose control in individuals with diabetes mellitus. Glucose levels closer to the time of the assay have a greater influence on the HbA1c level.

LREFGoldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care 1995;18:896-909.

The risk of diabetic complications, such as diabetic nephropathy and retinopathy, increases with poor metabolic control. In accordance with its function as an indicator for the mean blood glucose level, HbA1c predicts the development of diabetic complications in diabetes patients.

LREFThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.
,
LREFIntensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.

For routine clinical use, testing every 3 to 4 months is generally sufficient. In certain clinical situations, such as gestational diabetes, or after a major change in therapy, it may be useful to measure HbA1c in 2 to 4 week intervals.

LREFGoldstein DE, Little RR, Wiedmeyer HM, et al. Glycated hemoglobin: methodologies and clinical applications. Clin Chem 1986;32:B64-B70.

", "Language": "en" }, { "Name": "Reagents", "Value": "

Reagents – working solutions

R1

Antibody Reagent

MES buffer: 0.025 mol/L; TRIS buffer: 0.015 mol/L, pH 6.2; HbA1c antibody (ovine serum): ≥ 0.5 mg/mL; detergent; stabilizers; preservatives

R3

Polyhapten Reagent

MES buffer: 0.025 mol/L; TRIS buffer: 0.015 mol/L, pH 6.2; HbA1c polyhapten: ≥ 8 µg/mL; detergent; stabilizers; preservatives

Hemolyzing Reagent (Cat. No. 04528182190)

Aqueous buffered matrix, pH 7.25; tetradecyltrimethylammonium bromide: 36 g/L; sodium dihydrogenphosphate monohydrate: 16 mmol/L; sodium monohydrogenphosphate dihydrate: 64 mmol/L; stabilizers; preservatives

R1 is in position A and R3 is in position C. Position B contains H2O for technical reasons.

", "Language": "en" }, { "Name": "PrecautionsWarnings", "Value": "

Precautions and warnings

For in vitro diagnostic use.
Exercise the normal precautions required for handling all laboratory reagents.
Disposal of all waste material should be in accordance with local guidelines.
Safety data sheet available for professional user on request.

For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.

", "Language": "en" }, { "Name": "Caution", "Value": "", "Language": "en" }, { "Name": "QualityControl", "Value": "

Quality control

Quality control for Whole Blood and Hemolysate Application

For quality control, use control materials as listed in the \"Order information\" section.

In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory’s individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

", "Language": "en" }, { "Name": "SpecimenPreparation", "Value": "

Specimen collection and preparation

When using Na-heparin, NaF/potassium oxalate, or NaF/sodium EDTA with the whole blood application, fresh whole blood samples should be analyzed. Do not use whole blood stored > 8 hours. Hemolysate should be prepared and stored for analysis if whole blood cannot be analyzed within 8 hours of collection.

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable.

Anticoagulated venous or capillary blood or hemolysate. The only acceptable anticoagulants are Li-heparin, Na-heparin, K2‑EDTA, K3‑EDTA, potassium fluoride/Na2‑EDTA, NaF/sodium EDTA and NaF/potassium oxalate.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

See the limitations and interferences section for details about possible sample interferences.

Sample stability claims were established by experimental data by the manufacturer or based on reference literature and only for the temperatures/time frames as stated in the method sheet. It is the responsibility of the individual laboratory to use all available references and/or its own studies to determine specific stability criteria for its laboratory.

Stability:

3 days at 15‑25 °C

7 days at 2‑8 °C

6 months at (-15)‑(-25) °C

Frozen stability of HbA1c has not been determined for samples treated with anticoagulants Na-heparin, NaF/potassium oxalate or NaF/sodium EDTA.

Freeze only once. Mix specimen thoroughly after thawing.

Hemolysate preparation for Hemolysate Application

1. Allow blood specimen and Hemolyzing Reagent for Tina‑quant HbA1c to equilibrate at room temperature before use.

2. Moderately mix the sample immediately prior to pipetting to ensure a homogeneous mixture of erythrocytes. Take care to avoid the formation of foam.

3. Dilute the sample with Hemolyzing Reagent for Tina‑quant HbA1c (Cat. No. 11488457122) in the ratio 1:101 (1+100) using one of the following pipetting schemes.

Pipette into tubes:

HbA1c Hemolyzing Reagent for Tina‑quant HbA1c

500 µL

1000 µL

2000 µL

Specimen (patient or control)

5 µL

10 µL

20 µL

4. Mix using a vibration mixer or by gentle swirling.

5. The hemolysate can be used after the solution has changed color from red to brownish-green (approx. 1‑2 min).

Stability of the hemolysate:

4 hours at 15‑25 °C

24 hours at 2‑8 °C

6 months at (-15)‑(-25) °C

Frozen stability of HbA1c has not been determined for samples treated with anticoagulants Na-heparin, NaF/potassium oxalate or NaF/sodium EDTA.

", "Language": "en" } ] } }, { "ProductSpecVariant": { "MetaData": { "DocumentMaterialNumber": "0105336163190COIN", "ProductName": "A1C-3", "ProductLongName": "Tina-quant Hemoglobin A1c Gen.3 - Whole blood application - Standardized according to IFCC transferable to DCCT/NGSP", "Language": "en", "DocumentVersion": "3", "DocumentObjectID": "FF00000004A8AA0E", "DocumentOriginID": "FF00000001BFB10E", "MaterialNumbers": [ "05336163190" ], "InstrumentReferences": [ { "ID": "302", "BrandName": "COBAS INTEGRA 400 plus" } ], "DisclaimerText": "Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative." }, "Chapters": [ { "Name": "IntendedUse", "Value": "

Intended use

In vitro test for the quantitative determination of mmol/mol hemoglobin A1c (IFCC) and % hemoglobin A1c (DCCT/NGSP) in whole blood on Roche clinical chemistry analyzers. HbA1c determinations are useful for monitoring of long-term blood glucose control in individuals with diabetes mellitus. Moreover, this test is to be used as an aid in diagnosis of diabetes and identifying patients who may be at risk for developing diabetes.

", "Language": "en" }, { "Name": "TestPrinciple", "Value": "

Test principle

Test principle

LREFZander R, Lang W, Wolf HU. Alkaline haematin D-575, a new tool for the determination of haemoglobin as an alternative to the cyanhaemiglobin method. I. Description of the method. Clin Chim Acta 1984;136:83-93.
,
LREFWolf HU, Lang W, Zander R. Alkaline haematin D-575, a new tool for the determination of haemoglobin as an alternative to the cyanhaemiglobin method. II. Standardization of the method using pure chlorohaemin. Clin Chim Acta 1984;136:95-104.
,
LREFLittle RR, Wiedmeyer HM, England JD, et al. Interlaboratory standardization of measurements of glycohemoglobins. Clin Chem 1992;38:2472-2478.

The anticoagulated whole blood specimen is hemolyzed automatically on the COBAS INTEGRA 400 plus analyzer with COBAS INTEGRA Hemolyzing Reagent Gen.2. This method uses TTAB

FREFTTAB = Tetradecyltrimethylammonium bromide
as the detergent in the hemolyzing reagent to eliminate interference from leukocytes (TTAB does not lyse leukocytes). Sample pretreatment to remove labile HbA1c is not necessary.

All hemoglobin variants which are glycated at the β‑chain N‑terminus and which have antibody-recognizable regions identical to that of HbA1c are determined by this assay. Consequently, the metabolic state of diabetic patients having uremia or the most frequent hemoglobinopathies (HbAS, HbAC, HbAD, HbAE) can be determined by this assay.

LREFFrank EL, Moulton L, Little RR, et al. Effects of hemoglobin C and S traits on seven glycated hemoglobin methods. Clin Chem 2000;46(6):864-867.
,
LREFChang J, Hoke C, Ettinger B, et al. Evaluation and Interference Study of Hemoglobin A1c Measured by Turbidimetric Inhibition Immunoassay. Am J Clin Pathol 1998;109(3):274-278.
,
LREFJaisson S, Leroy N, Gillery P, et al. Evaluation of the analytical performances of the Cobas c513 analyser for HbA1c assay. Biochem Med 2018;28(3):030708

Hemoglobin A1c

The HbA1c determination is based on the turbidimetric inhibition immunoassay (TINIA) for hemolyzed whole blood.

  • Sample and addition of R1 (buffer/antibody):
    Glycohemoglobin (HbA1c) in the sample reacts with anti-HbA1c antibody to form soluble antigen-antibody complexes. Since the specific HbA1c antibody site is present only once on the HbA1c molecule, complex formation does not take place.

  • Addition of SR (buffer/polyhapten) and start of reaction:
    The polyhaptens react with excess anti-HbA1c antibodies to form an insoluble antibody-polyhapten complex which can be determined turbidimetrically.

Hemoglobin

Liberated hemoglobin in the hemolyzed sample is converted to a derivative having a characteristic absorption spectrum which is measured bichromatically during the preincubation phase (sample + R1) of the above immunological reaction. A separate Hb reagent is consequently not necessary.

The final result is expressed as mmol/mol HbA1c or % HbA1c and is calculated from the HbA1c/Hb ratio as follows:

Protocol 1 (mmol/mol HbA1c acc. to IFCC):
HbA1c (mmol/mol) = (HbA1c/Hb) × 1000

Protocol 2 (% HbA1c acc. to DCCT/NGSP):
HbA1c (%) = (HbA1c/Hb) × 91.5 + 2.15

", "Language": "en" }, { "Name": "MeasuringRange", "Value": "

Limits and ranges

Measuring range

Hb: 2.48‑24.8 mmol/L (4‑40 g/dL)
HbA1c: 0.186‑1.61 mmol/L (0.3‑2.6 g/dL)

This corresponds to a measuring range of 23‑196 mmol/mol HbA1c (IFCC) and 4.2‑20.1 % HbA1c (DCCT/NGSP) at a typical hemoglobin concentration of 8.2 mmol/L (13.2 g/dL).

Lower limits of measurement

Limit of Blank and Limit of Detection

Hb:

Limit of Blank

= 0.31 mmol/L (0.50 g/dL)

Limit of Detection

= 0.62 mmol/L (1.00 g/dL)

HbA1c:

Limit of Blank

= 0.12 mmol/L (0.19 g/dL)

Limit of Detection

= 0.18 mmol/L (0.29 g/dL)

The Limit of Blank and Limit of Detection were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17‑A requirements.

The Limit of Blank is the 95th percentile value from n ≥ 60 measurements of analyte‑free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte‑free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples.

The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

", "Language": "en" }, { "Name": "ExpectedValues", "Value": "

Expected values

Protocol 1 (mmol/mol HbA1c acc. to IFCC): 29‑42 mmol/mol HbA1c

LREFJunge W, Wilke B, Halabi A, et al. Determination of reference intervals in adults for hemoglobin A1c (HbA1c). Poster presentation 18th International Diabetes Federation Congress, Paris, 2003.

Protocol 2 (% HbA1c acc. to DCCT/NGSP): 4.8‑5.9 % HbA1c

LREFJunge W, Wilke B, Halabi A, et al. Determination of reference intervals in adults for hemoglobin A1c (HbA1c). Poster presentation 18th International Diabetes Federation Congress, Paris, 2003.

This reference range was obtained by measuring 482 well-characterized healthy individuals without diabetes mellitus. HbA1c levels higher than the upper end of this reference range are an indication of hyperglycemia during the preceding 2 to 3 months or longer. According to the recommendations of the American Diabetes Association values above 48 mmol/mol HbA1c (IFCC) or 6.5 % HbA1c (DCCT/NGSP) are suitable for the diagnosis of diabetes mellitus.

LREFInternational Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care 2009;32(7):1327-1334.
,
LREFDiagnosis and Classification of Diabetes Mellitus. Diabetes Care 2010;33(1):62-69.
Patients with HbA1c values in the range of 39‑46 mmol/mol HbA1c (IFCC) or 5.7‑6.4 % HbA1c (DCCT/NGSP) may be at a risk of developing diabetes.
LREFInternational Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care 2009;32(7):1327-1334.
,
LREFDiagnosis and Classification of Diabetes Mellitus. Diabetes Care 2010;33(1):62-69.

HbA1c levels may reach 195 mmol/mol (IFCC) or 20 % (DCCT/NGSP) or higher in poorly controlled diabetes. Therapeutic action is suggested at levels above 64 mmol/mol HbA1c (IFCC) or 8 % HbA1c (DCCT/NGSP). Diabetes patients with HbA1c levels below 53 mmol/mol HbA1c (IFCC) or 7 % HbA1c (DCCT/NGSP) meet the goal of the American Diabetes Association.

LREFAmerican Diabetes Association. Standards of Medical Care for patients with diabetes mellitus. Diabetes Care [Suppl.] 1995;18(1):8-15.
,
LREFSacks BW, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002;48:436-472.

HbA1c levels below the established reference range may indicate recent episodes of hypoglycemia, the presence of Hb variants, or shortened lifetime of erythrocytes.

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

", "Language": "en" }, { "Name": "LimitationInterference", "Value": "

Limitations - interference

Limitations - interference

LREFFrank EL, Moulton L, Little RR, et al. Effects of hemoglobin C and S traits on seven glycated hemoglobin methods. Clin Chem 2000;46(6):864-867.
,
LREFChang J, Hoke C, Ettinger B, et al. Evaluation and Interference Study of Hemoglobin A1c Measured by Turbidimetric Inhibition Immunoassay. Am J Clin Pathol 1998;109(3):274-278.
,
LREFMartina WV, Martijn EG, van der Molen M, et al. β-N-terminal glycohemoglobins in subjects with common hemoglobinopathies: relation with fructosamine and mean erythrocyte age. Clin Chem 1993;39:2259-2265.
,
LREFWeykamp CW, Penders TJ, Muskiet FAJ, et al. Influence of hemoglobin variants and derivatives on glycohemoglobin determinations, as investigated by 102 laboratories using 16 methods. Clin Chem 1993;39:1717-1723.
,
LREFAmerican Diabetes Association. Standards of Medical Care for patients with diabetes mellitus. Diabetes Care [Suppl.] 1995;18(1):8-15.
,
LREFSacks BW, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002;48:436-472.
,
LREFGlick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
,
LREFMiedema K. Influence of hemoglobin variants on the determination of glycated hemoglobin. Klin Lab 1993;39:1029-1032.
,
LREFNiederau C, Coe A, Katayama Y. Interference of Non-glucose Adducts on the Determination of Glycated Hemoglobins. Klin Lab 1993;39:1015-1023.
,
LREFRohlfing C, Connolly S, England J, et al. Effect of elevated fetal hemoglobin on HbA1c measurements: four common assay methods compared to the IFCC reference method. Clin Chem 2006;52 Suppl 6:A108.

  1. For diagnostic purposes, mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP) should be used in conjunction with information from other diagnostic procedures and clinical evaluations.

  2. The test is designed only for accurate and precise measurement of mmol/mol HbA1c (IFCC) and % HbA1c (DCCT/NGSP). The individual results for total Hb and HbA1c concentration should not be reported.

  3. As a matter of principle, care must be taken when interpreting any HbA1c result from patients with Hb variants. Abnormal hemoglobins might affect the half life of the red cells or the in vivo glycation rates. In these cases even analytically correct results do not reflect the same level of glycemic control that would be expected in patients with normal hemoglobin.

    LREFMiedema K. Influence of hemoglobin variants on the determination of glycated hemoglobin. Klin Lab 1993;39:1029-1032.

    Whenever it is suspected that the presence of an Hb variant (e.g. HbSS, HbCC, or HbSC) affects the correlation between the HbA1c value and glycemic control HbA1c must not be used for the diagnosis of diabetes mellitus.

  4. Any cause of shortened erythrocyte survival or decrease in mean erythrocyte age will reduce exposure of erythrocytes to glucose with a consequent decrease in mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP), even though the time-averaged blood glucose level may be elevated. Causes of shortened erythrocyte lifetime might be hemolytic anemia or other hemolytic diseases, homozygous sickle cell trait, pregnancy, recent significant or chronic blood loss, etc. Similarly, recent blood transfusions can alter the mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP). Caution should be used when interpreting the HbA1c results from patients with these conditions. HbA1c must not be used for the diagnosis of diabetes mellitus in the presence of such conditions.

  5. Glycated HbF is not detected as it does not contain the glycated β‑chain that characterizes HbA1c. However, HbF is measured in the Total Hb assay and as a consequence, specimens containing high amounts of HbF (> 10 %) may result in lower than expected mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP).

    LREFChang J, Hoke C, Ettinger B, et al. Evaluation and Interference Study of Hemoglobin A1c Measured by Turbidimetric Inhibition Immunoassay. Am J Clin Pathol 1998;109(3):274-278.
    ,
    LREFRohlfing C, Connolly S, England J, et al. Effect of elevated fetal hemoglobin on HbA1c measurements: four common assay methods compared to the IFCC reference method. Clin Chem 2006;52 Suppl 6:A108.

  6. mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP) are not suitable for diagnosis of gestational diabetes.

    LREFInternational Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care 2009;32(7):1327-1334.

  7. In very rare cases of rapidly evolving type 1 diabetes the increase of HbA1c values might be delayed compared to the acute increase in glucose concentrations. In these conditions diabetes mellitus must be diagnosed based on plasma glucose concentrations and/or the typical clinical symptoms.

    LREFInternational Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care 2009;32(7):1327-1334.

Criterion: Recovery within ± 10 % of initial value.

Icterus: No significant interference up to a conjugated and unconjugated bilirubin concentration of 1026 μmol/L or 60 mg/dL.

Lipemia (Intralipid): No significant interference up to an Intralipid concentrationof 600 mg/dL. There is poor correlation between the triglycerides concentration and turbidity.

Glycemia: No significant interference up to a glucose concentration of 55.5 mmol/L or 1000 mg/dL. A fasting sample is not required.

Rheumatoid factors: No significant interference up to a rheumatoid factor concentration of 750 IU/mL.

Drugs: No interference was found at therapeutic concentrations using common drug panels.

LREFBreuer J. Report on the Symposium "Drug Effects in Clinical Chemistry Methods". Eur J Clin Chem Clin Biochem 1996;34:385-386.
,
LREFSonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001;38:376-385.

Other: No cross reactions with HbA0, HbA1a, HbA1b, acetylated hemoglobin, carbamylated hemoglobin, glycated albumin and labile HbA1c were found for the anti-HbA1c antibodies used in this kit.

For diagnostic purposes, the results should always be assessed in conjunction with the patient’s medical history, clinical examination and other findings.

ACTION REQUIRED
Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on COBAS INTEGRA analyzers. Refer to the CLEAN Method Sheet for further instructions and for the latest version of the Extra wash cycle list.
Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.

", "Language": "en" }, { "Name": "OrderInformation", "Value": "

Order Information

Order information

Analyzer(s) on which cobas c pack(s) can be used

05336163 190

Tina-quant Hemoglobin A1c Gen.3 (150 tests)

System-ID 07 7455 3

COBAS INTEGRA 400 plus

Materials required (but not provided):

04528417 190

C.f.a.s. HbA1c (3 × 2 mL)

System-ID 07 6852 9

05479207 190

PreciControl HbA1c norm (4 × 1 mL)

System-ID 07 7477 4

05912504 190

PreciControl HbA1c path (4 × 1 mL)

System-ID 07 7478 2

04528328 190

COBAS INTEGRA Hemolyzing Reagent Gen.2 (6 × 10 mL)

System-ID 07 6851 0

", "Language": "en" }, { "Name": "SystemInformation", "Value": "

System information

Multitest A1CW3, test ID 0‑264

Test HB‑W3, test ID 0‑265; test A1‑W3, test ID 0‑266

Ratio RWD3, test ID 0‑275 (% HbA1c acc. to DCCT/NGSP)

Ratio RWI3, test ID 0‑274 (mmol/mol HbA1c acc. to IFCC)

Profile PA1W3, test ID 0‑273

", "Language": "en" }, { "Name": "Handling", "Value": "

Reagent handling

Ready for use

", "Language": "en" }, { "Name": "TestDefinition", "Value": "

Applications for Hb and HbA1c

COBAS INTEGRA 400 plus test definition Hb

Abbreviated test name

HB-W3

Measuring mode

Absorbance

Abs. calculation mode

Endpoint

Reaction mode

R1-S

Reaction direction

Increase

Wavelength A/B

378/659 nm

Calc. first/last

17/33

Predilution factor

100

Unit

mmol/L

Pipetting parameters

Hb

Diluent (H2O)

R1

120 µL

Sample

6 µL

0 µL

Total volume

126 µL

COBAS INTEGRA 400 plus test definition HbA1c

Abbreviated test name

A1-W3

Measuring mode

Absorbance

Abs. calculation mode

Endpoint

Reaction mode

R1-S-SR

Reaction direction

Increase

Wavelength A/B

340/659 nm

Calc. first/last

33/57

Predilution factor

100

Unit

mmol/L

Pipetting parameters

HbA1c

Diluent (H2O)

R1

120 µL

Sample

6 µL

0 µL

SR

24 µL

0 µL

Total volume

150 µL

Ratio definition for mmol/mol HbA1c and % HbA1c calculation

Protocol 1 (mmol/mol HbA1c acc. to IFCC):

Abbreviated ratio name

RWI3 (0-274)

Equation

(A1-W3/HB-W3) × 1000

Unit

mM/M

Protocol 2 (% HbA1c acc. to DCCT/NGSP):

Abbreviated ratio name

RWD3 (0-275)

Equation

(A1-W3/HB-W3) × 91.5 + 2.15

Unit

%

Use the predefined profile (PA1W3, 0‑273) for simultaneous order entry of Hb (HB‑W3) and HbA1c (A1‑W3) tests from the same sample.

The ratio for HbA1c (mmol/mol HbA1c acc. to IFCC and % HbA1c acc. to DCCT/NGSP) will be automatically calculated after result output of both tests.

For dual reporting of both mmol/mol HbA1c (IFCC) units as well as % HbA1c (DCCT/NGSP) units please ensure that both ratio tests 0‑274 (acc. to IFCC) and 0‑275 (acc. to DCCT/NGSP) are activated.

", "Language": "en" }, { "Name": "StorageStability", "Value": "

Storage and stability

Reagent

Shelf life at 2‑8 °C

See expiration date on cobas c pack label

COBAS INTEGRA 400 plus system

On-board in use at 10‑15 °C

4 weeks

Reagent cannot be frozen.
If freezing of a cassette is suspected a control measurement with this cassette is recommended.

Hemolyzing reagent

Shelf life at 2‑8 °C

See expiration date on bottle label

COBAS INTEGRA 400 plus system

On-board in use, ISE rack, closed bottles

4 weeks

On-board in use, multi rack, open bottles

2 days

When storing at temperatures under 3 °C, the reagent may become cloudy. This has no effect on the function of the reagent and is reversible at higher temperatures. It is therefore recommended to equilibrate the reagent at room temperature for approximately 10 minutes and mix thoroughly before use.

", "Language": "en" }, { "Name": "Calibration", "Value": "

Calibration

Hb

Calibrator

C.f.a.s. HbA1c

HbA1c

Calibrator

C.f.a.s. HbA1c

Calibration dilution ratio

1:1, 1:1.5, 1:2.1, 1:3, 1:6, 1:15, performed automatically by the instrument

Calibrator diluent

COBAS INTEGRA Hemolyzing Reagent Gen.2, Cat. No. 04528328190

Calibration mode

Spline

Calibration replicate

Duplicate recommended

Calibration interval

Each lot, every 29 days, and as required following quality control procedures

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Traceability: This method has been standardized against the approved IFCC reference method for the measurement of HbA1c in human blood

LREFKobold U, Jeppsson JO, Duelffer T, et al. Candidate reference methods for hemoglobin A1c based on peptide mapping. Clin Chem 1997;43:1944-1951.
,
LREFJeppsson JO, Kobold U, Finke A, et al. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med 2002;40:78-89.
and can be transferred to results traceable to DCCT/NGSP by calculation.

Note

Enter the assigned lot-specific and application-specific value of the calibrator. Use the appropriate C.f.a.s. HbA1c calibrator only. COBAS INTEGRA Hemolyzing Reagent Gen.2, 6 × 11 mL, Cat. No. 04528328190, system‑ID 07 6851 0, needs to be available on the analyzer. Otherwise the calibration cannot be carried out.

", "Language": "en" }, { "Name": "Limitations", "Value": "", "Language": "en" }, { "Name": "PerformanceData", "Value": "

Specific performance data

Representative performance data on the COBAS INTEGRA analyzers are given below. Results obtained in individual laboratories may differ.

", "Language": "en" }, { "Name": "Precision", "Value": "

Precision

Repeatability and intermediate precision were determined using human samples and controls in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP5 requirements (2 aliquots per run, 2 runs per day, 21 days). The following results were obtained (data based on DCCT/NGSP values):

Repeatability

Mean
% HbA1c

SD
% HbA1c

CV
%

PreciControl HbA1c norm

5.81

0.09

1.6

PreciControl HbA1c path

10.6

0.09

0.8

Human sample 1

5.37

0.09

1.7

Human sample 2

6.43

0.08

1.3

Human sample 3

7.50

0.10

1.4

Human sample 4

8.52

0.08

0.9

Human sample 5

10.9

0.09

0.8

Intermediate precision

Mean
% HbA1c

SD
% HbA1c

CV
%

PreciControl HbA1c norm

5.74

0.12

2.1

PreciControl HbA1c path

10.6

0.18

1.7

Human sample 1

5.35

0.12

2.3

Human sample 2

6.33

0.12

1.9

Human sample 3

7.50

0.14

1.8

Human sample 4

8.52

0.12

1.4

Human sample 5

10.7

0.21

1.9

", "Language": "en" }, { "Name": "MethodComparison", "Value": "

Method comparison

Evaluation of method comparison data is according to former NGSP certification criteria. The mean difference between the two methods and the 95 % confidence intervals of the differences in the range from 4‑10 % (DCCT/NGSP) are given. 95 % of the differences between the values obtained for individual samples with both methods fall within the range defined by the lower and upper 95 % confidence intervals of the differences.

% HbA1c (DCCT/NGSP) values for human blood samples obtained on a COBAS INTEGRA 400 plus analyzer using the Tina‑quant Hemoglobin A1c Gen.3 reagent with the whole blood application (y) were compared with those determined using the same reagent with the whole blood application on a cobas c 501 analyzer (x).

Sample size (n) = 96

Mean difference: 0.03 % HbA1c

Lower 95 % confidence interval of differences: −0.45 % HbA1c

Upper 95 % confidence interval of differences: 0.51 % HbA1c

The sample concentrations were between 4.30 and 11.7 % HbA1c (DCCT/NGSP).

", "Language": "en" }, { "Name": "Summary", "Value": "

Summary

Summary

LREFGoldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care 1995;18:896-909.
,
LREFGoldstein DE, Little RR. More than you ever wanted to know (but need to know) about glycohemoglobin testing. Diabetes Care 1994;17:938-939.
,
LREFThe Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
,
LREFUK Prospective Diabetes Study (UKPDS) group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
,
LREFFinke A, Kobold U, Hoelzel W, et al. Preparation of a candidate primary reference material for the international standardization of HbA1c determinations. Clin Chem Lab Med 1998;36(5):299-308.
,
LREFGoldstein DE, Little RR, Wiedmeyer HM, et al. Glycated hemoglobin: methodologies and clinical applications. Clin Chem 1986;32:B64-B70.
,
LREFNathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008;31:1473-1478.
,
LREFBunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 1978;200:21-27.

Hemoglobin (Hb) consists of four protein subunits, each containing a heme moiety, and is the red-pigmented protein located in the erythrocytes. Its main function is to transport oxygen and carbon dioxide in blood. Each Hb molecule is able to bind four oxygen molecules. Hb consists of a variety of subfractions and derivatives. Among this heterogeneous group of hemoglobins HbA1c is one of the glycated hemoglobins, a subfraction formed by the attachment of various sugars to the Hb molecule. HbA1c is formed in two steps by the nonenzymatic reaction of glucose with the N‑terminal amino group of the β‑chain of normal adult Hb (HbA). The first step is reversible and yields labile HbA1c. This is rearranged to form stable HbA1c in a second reaction step.

In the erythrocytes, the relative amount of HbA converted to stable HbA1c increases with the average concentration of glucose in the blood. The conversion to stable HbA1c is limited by the erythrocyte’s life span of approximately 100 to 120 days. As a result, HbA1c reflects the average blood glucose level during the preceding 2 to 3 months. HbA1c is thus suitable to monitor long-term blood glucose control in individuals with diabetes mellitus. Glucose levels closer to the time of the assay have a greater influence on the HbA1c level.

LREFGoldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care 1995;18:896-909.

The approximate relationship between HbA1c and mean blood glucose values during the preceding 2 to 3 months was analyzed in several studies. A recent study obtained the following correlation:

IFCC standardization (recalculated acc. to ref. 8)

• Estimated average glucose [mmol/L] = 0.146 × HbA1c (mmol/mol) + 0.834

or

• Estimated average glucose [mg/dL] = 2.64 × HbA1c (mmol/mol) + 15.03

Standardization acc. to DCCT/NGSP

LREFGoldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care 1995;18:896-909.

• Estimated average glucose [mmol/L] = 1.59 × HbA1c (%) - 2.59

or

• Estimated average glucose [mg/dL] = 28.7 × HbA1c (%) - 46.7

The risk of diabetic complications, such as diabetic nephropathy and retinopathy, increases with poor metabolic control. In accordance with its function as an indicator for the mean blood glucose level, HbA1c predicts the development of diabetic complications in diabetes patients.

LREFThe Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
,
LREFUK Prospective Diabetes Study (UKPDS) group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.

For monitoring of long term glycemic control, testing every 3 to 4 months is generally sufficient. In certain clinical situations, such as gestational diabetes, or after a major change in therapy, it may be useful to measure HbA1c in 2 to 4 week intervals.

LREFGoldstein DE, Little RR, Wiedmeyer HM, et al. Glycated hemoglobin: methodologies and clinical applications. Clin Chem 1986;32:B64-B70.

", "Language": "en" }, { "Name": "Reagents", "Value": "

Reagents - working solutions

R1

Antibody reagent
MES

FREFMES = 2-morpholinoethane sulfonic acid
buffer: 0.025 mol/L; TRIS
FREFTRIS = Tris(hydroxymethyl)-aminomethane
buffer: 0.015 mol/L, pH 6.2; HbA1c antibody (ovine serum): ≥ 0.5 mg/mL; detergents; stabilizers; preservative

SR

Polyhapten reagent
MES buffer: 0.025 mol/L; TRIS buffer: 0.015 mol/L, pH 6.2; HbA1c polyhapten: ≥ 8 µg/mL; detergents; stabilizers; preservative

R1 is in position A and SR is in position C.

", "Language": "en" }, { "Name": "PrecautionsWarnings", "Value": "

Precautions and warnings

For in vitro diagnostic use for health care professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste:
Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards:
Apply all relevant local disposal regulations to determine the safe disposal.

Safety data sheet available for professional user on request.

This kit contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:

Warning

H317

May cause an allergic skin reaction.

Prevention:

P261

Avoid breathing dust/fume/gas/mist/vapours/spray.

P272

Contaminated work clothing should not be allowed out of the workplace.

P280

Wear protective gloves.

Response:

P333 + P313

If skin irritation or rash occurs: Get medical advice/attention.

P362 + P364

Take off contaminated clothing and wash it before reuse.

Disposal:

P501

Dispose of contents/container to an approved waste disposal plant.

Product safety labeling follows EU GHS guidance.

Contact phone: all countries: +49-621-7590

", "Language": "en" }, { "Name": "Caution", "Value": "", "Language": "en" }, { "Name": "QualityControl", "Value": "

Quality control

Quality control

PreciControl HbA1c norm

PreciControl HbA1c path

Control interval

24 hours recommended

Control sequence

User defined

Control after calibration

Recommended

For quality control, use control materials as listed in the \"Order information\" section. In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory’s individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Note

Pretreat controls in the same way as samples.
HbA1c controls carry a declaration for mmol/mol HbA1c (IFCC) and % HbA1c (DCCT/NGSP) only. No declarations for Hb and HbA1c concentrations are provided. As a consequence, HbA1c controls are handled like samples and cannot be included in the COBAS INTEGRA systems Quality Control Program.

", "Language": "en" }, { "Name": "SpecimenPreparation", "Value": "

Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable.
Anticoagulated venous or capillary blood

The only acceptable anticoagulants are Li-Heparin, K2‑EDTA, K3‑EDTA, Fluoride/Na2‑EDTA, Na‑Heparin and Fluoride/potassium oxalate.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

See the limitations and interferences section for details about possible sample interferences.

Stability:

3 days at 15‑25 °C

7 days at 2‑8 °C

6 months at (‑15)‑(‑25) °C

The recovery of HbA1c ratio values from sedimented samples, especially in case of poorly controlled diabetic patients, may be slightly elevated. To minimize this effect samples may be gently mixed by inversion prior to analysis.

Freeze only once. Mix specimen thoroughly after thawing.

", "Language": "en" } ] } }, { "ProductSpecVariant": { "MetaData": { "DocumentMaterialNumber": "0105336163190COIN", "ProductName": "A1C-3", "ProductLongName": "Tina-quant Hemoglobin A1c Gen.3 - Hemolysate Application - Standardized according to IFCC transferable to DCCT/NGSP", "Language": "en", "DocumentVersion": "2", "DocumentObjectID": "FF0000000413540E", "DocumentOriginID": "FF00000001BF8D0E", "MaterialNumbers": [ "05336163190" ], "InstrumentReferences": [ { "ID": "302", "BrandName": "COBAS INTEGRA 400 plus" } ], "DisclaimerText": "Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative." }, "Chapters": [ { "Name": "IntendedUse", "Value": "

Intended use

In vitro test for the quantitative determination of mmol/mol hemoglobin A1c (IFCC) and % hemoglobin A1c (DCCT/NGSP) in hemolysate prepared from whole blood on Roche clinical chemistry analyzers. HbA1c determinations are useful for monitoring of long-term blood glucose control in individuals with diabetes mellitus. Moreover, this test is to be used as an aid in diagnosis of diabetes and identifying patients who may be at risk for developing diabetes.

", "Language": "en" }, { "Name": "TestPrinciple", "Value": "

Test principle

Test principle

LREFZander R, Lang W, Wolf HU. Alkaline haematin D-575, a new tool for the determination of haemoglobin as an alternative to the cyanhaemiglobin method. I. Description of the method. Clin Chim Acta 1984;136:83-93.
,
LREFWolf HU, Lang W, Zander R. Alkaline haematin D-575, a new tool for the determination of haemoglobin as an alternative to the cyanhaemiglobin method. II. Standardization of the method using pure chlorohaemin. Clin Chim Acta 1984;136:95-104.
,
LREFLittle RR, Wiedmeyer HM, England JD, et al. Interlaboratory standardization of measurements of glycohemoglobins. Clin Chem 1992;38:2472-2478.

This method uses TTAB

FREFTTAB = Tetradecyltrimethylammonium bromide
as the detergent in the hemolyzing reagent to eliminate interference from leukocytes (TTAB does not lyse leukocytes). Sample pretreatment to remove labile HbA1c is not necessary.

All hemoglobin variants which are glycated at the β‑chain N‑terminus and which have antibody-recognizable regions identical to that of HbA1c are determined by this assay. Consequently, the metabolic state of diabetic patients having uremia or the most frequent hemoglobinopathies (HbAS, HbAC, HbAD, HbAE) can be determined by this assay.

LREFFrank EL, Moulton L, Little RR, et al. Effects of hemoglobin C and S traits on seven glycated hemoglobin methods. Clin Chem 2000;46(6):864-867.
,
LREFChang J, Hoke C, Ettinger B, et al. Evaluation and Interference Study of Hemoglobin A1c Measured by Turbidimetric Inhibition Immunoassay. Am J Clin Pathol 1998;109(3):274-278.
,
LREFJaisson S, Leroy N, Gillery P, et al. Evaluation of the analytical performances of the Cobas c513 analyser for HbA1c assay. Biochem Med 2018;28(3):030708

Hemoglobin A1c

The HbA1c determination is based on the turbidimetric inhibition immunoassay (TINIA) for hemolyzed whole blood.

  • Sample and addition of R1 (buffer/antibody):
    Glycohemoglobin (HbA1c) in the sample reacts with anti-HbA1c antibody to form soluble antigen-antibody complexes. Since the specific HbA1c antibody site is present only once on the HbA1c molecule, complex formation does not take place.

  • Addition of SR (buffer/polyhapten) and start of reaction:
    The polyhaptens react with excess anti-HbA1c antibodies to form an insoluble antibody-polyhapten complex which can be determined turbidimetrically.

Hemoglobin

Liberated hemoglobin in the hemolyzed sample is converted to a derivative having a characteristic absorption spectrum which is measured bichromatically during the preincubation phase (sample + R1) of the above immunological reaction. A separate Hb reagent is consequently not necessary.

The final result is expressed as mmol/mol HbA1c or % HbA1c and is calculated from the HbA1c/Hb ratio as follows:

Protocol 1 (mmol/mol HbA1c acc. to IFCC):
HbA1c (mmol/mol) = (HbA1c/Hb) × 1000

Protocol 2 (% HbA1c acc. to DCCT/NGSP):
HbA1c (%) = (HbA1c/Hb) × 91.5 + 2.15

", "Language": "en" }, { "Name": "MeasuringRange", "Value": "

Limits and ranges

Measuring range

Hb: 2.48‑24.8 mmol/L (4‑40 g/dL)
HbA1c: 0.186‑1.61 mmol/L (0.3‑2.6 g/dL)

This corresponds to a measuring range of 23‑196 mmol/mol HbA1c (IFCC) and 4.2‑20.1 % HbA1c (DCCT/NGSP) at a typical hemoglobin concentration of 8.2 mmol/L (13.2 g/dL).

Lower limits of measurement

Limit of Blank and Limit of Detection

Hb:

Limit of Blank

= 0.31 mmol/L (0.50 g/dL)

Limit of Detection

= 0.62 mmol/L (1.00 g/dL)

HbA1c:

Limit of Blank

= 0.12 mmol/L (0.19 g/dL)

Limit of Detection

= 0.18 mmol/L (0.29 g/dL)

The Limit of Blank and Limit of Detection were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17‑A requirements.

The Limit of Blank is the 95th percentile value from n ≥ 60 measurements of analyte‑free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte‑free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples.

The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

", "Language": "en" }, { "Name": "ExpectedValues", "Value": "

Expected values

Protocol 1 (mmol/mol HbA1c acc. to IFCC): 29‑42 mmol/mol HbA1c

LREFJunge W, Wilke B, Halabi A, et al. Determination of reference intervals in adults for hemoglobin A1c (HbA1c). Poster presentation 18th International Diabetes Federation Congress, Paris, 2003.

Protocol 2 (% HbA1c acc. to DCCT/NGSP): 4.8‑5.9 % HbA1c

LREFJunge W, Wilke B, Halabi A, et al. Determination of reference intervals in adults for hemoglobin A1c (HbA1c). Poster presentation 18th International Diabetes Federation Congress, Paris, 2003.

This reference range was obtained by measuring 482 well-characterized healthy individuals without diabetes mellitus. HbA1c levels higher than the upper end of this reference range are an indication of hyperglycemia during the preceding 2 to 3 months or longer. According to the recommendations of the American Diabetes Association values above 48 mmol/mol HbA1c (IFCC) or 6.5 % HbA1c (DCCT/NGSP) are suitable for the diagnosis of diabetes mellitus.

LREFInternational Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care 2009;32(7):1327-1334.
,
LREFDiagnosis and Classification of Diabetes Mellitus. Diabetes Care 2010;33(1):62-69.
Patients with HbA1c values in the range of 39‑46 mmol/mol HbA1c (IFCC) or 5.7‑6.4 % HbA1c (DCCT/NGSP) may be at a risk of developing diabetes.
LREFInternational Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care 2009;32(7):1327-1334.
,
LREFDiagnosis and Classification of Diabetes Mellitus. Diabetes Care 2010;33(1):62-69.

HbA1c levels may reach 195 mmol/mol (IFCC) or 20 % (DCCT/NGSP) or higher in poorly controlled diabetes. Therapeutic action is suggested at levels above 64 mmol/mol HbA1c (IFCC) or 8 % HbA1c (DCCT/NGSP). Diabetes patients with HbA1c levels below 53 mmol/mol HbA1c (IFCC) or 7 % HbA1c (DCCT/NGSP) meet the goal of the American Diabetes Association.

LREFAmerican Diabetes Association. Standards of Medical Care for patients with diabetes mellitus. Diabetes Care [Suppl.] 1995;18(1):8-15.
,
LREFSacks BW, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002;48:436-472.

HbA1c levels below the established reference range may indicate recent episodes of hypoglycemia, the presence of Hb variants, or shortened lifetime of erythrocytes.

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

", "Language": "en" }, { "Name": "LimitationInterference", "Value": "

Limitations - interference

Limitations - interference

LREFFrank EL, Moulton L, Little RR, et al. Effects of hemoglobin C and S traits on seven glycated hemoglobin methods. Clin Chem 2000;46(6):864-867.
,
LREFChang J, Hoke C, Ettinger B, et al. Evaluation and Interference Study of Hemoglobin A1c Measured by Turbidimetric Inhibition Immunoassay. Am J Clin Pathol 1998;109(3):274-278.
,
LREFMartina WV, Martijn EG, van der Molen M, et al. β-N-terminal glycohemoglobins in subjects with common hemoglobinopathies: relation with fructosamine and mean erythrocyte age. Clin Chem 1993;39:2259-2265.
,
LREFWeykamp CW, Penders TJ, Muskiet FAJ, et al. Influence of hemoglobin variants and derivatives on glycohemoglobin determinations, as investigated by 102 laboratories using 16 methods. Clin Chem 1993;39:1717-1723.
,
LREFAmerican Diabetes Association. Standards of Medical Care for patients with diabetes mellitus. Diabetes Care [Suppl.] 1995;18(1):8-15.
,
LREFSacks BW, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002;48:436-472.
,
LREFGlick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
,
LREFMiedema K. Influence of hemoglobin variants on the determination of glycated hemoglobin. Klin Lab 1993;39:1029-1032.
,
LREFNiederau C, Coe A, Katayama Y. Interference of Non-glucose Adducts on the Determination of Glycated Hemoglobins. Klin Lab 1993;39:1015-1023.
,
LREFRohlfing C, Connolly S, England J, et al. Effect of elevated fetal hemoglobin on HbA1c measurements: four common assay methods compared to the IFCC reference method. Clin Chem 2006;52 Suppl 6:A108.

  1. For diagnostic purposes, mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP) should be used in conjunction with information from other diagnostic procedures and clinical evaluations.

  2. The test is designed only for accurate and precise measurement of mmol/mol HbA1c (IFCC) and % HbA1c (DCCT/NGSP). The individual results for total Hb and HbA1c concentration should not be reported.

  3. As a matter of principle, care must be taken when interpreting any HbA1c result from patients with Hb variants. Abnormal hemoglobins might affect the half life of the red cells or the in vivo glycation rates. In these cases even analytically correct results do not reflect the same level of glycemic control that would be expected in patients with normal hemoglobin.

    LREFMiedema K. Influence of hemoglobin variants on the determination of glycated hemoglobin. Klin Lab 1993;39:1029-1032.

    Whenever it is suspected that the presence of an Hb variant (e.g. HbSS, HbCC, or HbSC) affects the correlation between the HbA1c value and glycemic control HbA1c must not be used for the diagnosis of diabetes mellitus.

  4. Any cause of shortened erythrocyte survival or decrease in mean erythrocyte age will reduce exposure of erythrocytes to glucose with a consequent decrease in mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP), even though the time-averaged blood glucose level may be elevated. Causes of shortened erythrocyte lifetime might be hemolytic anemia or other hemolytic diseases, homozygous sickle cell trait, pregnancy, recent significant or chronic blood loss, etc. Similarly, recent blood transfusions can alter the mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP). Caution should be used when interpreting the HbA1c results from patients with these conditions. HbA1c must not be used for the diagnosis of diabetes mellitus in the presence of such conditions.

  5. Glycated HbF is not detected as it does not contain the glycated β‑chain that characterizes HbA1c. However, HbF is measured in the Total Hb assay and as a consequence, specimens containing high amounts of HbF (> 10 %) may result in lower than expected mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP).

    LREFChang J, Hoke C, Ettinger B, et al. Evaluation and Interference Study of Hemoglobin A1c Measured by Turbidimetric Inhibition Immunoassay. Am J Clin Pathol 1998;109(3):274-278.
    ,
    LREFRohlfing C, Connolly S, England J, et al. Effect of elevated fetal hemoglobin on HbA1c measurements: four common assay methods compared to the IFCC reference method. Clin Chem 2006;52 Suppl 6:A108.

  6. mmol/mol HbA1c values (IFCC) and % HbA1c values (DCCT/NGSP) are not suitable for diagnosis of gestational diabetes.

    LREFInternational Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care 2009;32(7):1327-1334.

  7. In very rare cases of rapidly evolving type 1 diabetes the increase of HbA1c values might be delayed compared to the acute increase in glucose concentrations. In these conditions diabetes mellitus must be diagnosed based on plasma glucose concentrations and/or the typical clinical symptoms.

    LREFInternational Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care 2009;32(7):1327-1334.

Criterion: Recovery within ± 10 % of initial value.

Icterus: No significant interference up to a conjugated and unconjugated bilirubin concentration of 1026 μmol/L or 60 mg/dL.

Lipemia (Intralipid): No significant interference up to an Intralipid concentrationof 600 mg/dL. There is poor correlation between the triglycerides concentration and turbidity.

Glycemia: No significant interference up to a glucose concentration of 55.5 mmol/L or 1000 mg/dL. A fasting sample is not required.

Rheumatoid factors: No significant interference up to a rheumatoid factor concentration of 750 IU/mL.

Drugs: No interference was found at therapeutic concentrations using common drug panels.

LREFBreuer J. Report on the Symposium "Drug Effects in Clinical Chemistry Methods". Eur J Clin Chem Clin Biochem 1996;34:385-386.
,
LREFSonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001;38:376-385.

Other: No cross reactions with HbA0, HbA1a, HbA1b, acetylated hemoglobin, carbamylated hemoglobin, glycated albumin and labile HbA1c were found for the anti-HbA1c antibodies used in this kit.

For diagnostic purposes, the results should always be assessed in conjunction with the patient’s medical history, clinical examination and other findings.

ACTION REQUIRED
Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on COBAS INTEGRA analyzers. Refer to the CLEAN Method Sheet for further instructions and for the latest version of the Extra wash cycle list.
Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.

", "Language": "en" }, { "Name": "OrderInformation", "Value": "

Order Information

Order information

Analyzer(s) on which cobas c pack(s) can be used

05336163190

Tina-quant Hemoglobin A1c Gen.3 (150 tests)

System-ID 07 7455 3

COBAS INTEGRA 400 plus

04528417190

C.f.a.s. HbA1c (3 × 2 mL)

System-ID 07 6852 9

05479207190

PreciControl HbA1c norm (4 × 1 mL)

System-ID 07 7477 4

05912504190

PreciControl HbA1c path (4 × 1 mL)

System-ID 07 7478 2

11488457122

Hemolyzing Reagent for Tina-quant HbA1c (1000 mL)

04528328190

COBAS INTEGRA Hemolyzing Reagent Gen.2 (6 × 10 mL)

System-ID 07 6851 0

", "Language": "en" }, { "Name": "SystemInformation", "Value": "

System information

Multitest A1CH3, test ID 0‑588

Test HB‑H3, test ID 0‑589; test A1‑H3, test ID 0‑590

Ratio RHD3, test ID 0‑622 (% HbA1c acc. to DCCT/NGSP)

Ratio RHI3, test ID 0‑621 (mmol/mol HbA1c acc. to IFCC)

Profile PA1H3, test ID 0‑620

", "Language": "en" }, { "Name": "Handling", "Value": "

Reagent handling

Ready for use

", "Language": "en" }, { "Name": "TestDefinition", "Value": "

Applications for Hb and HbA1c

COBAS INTEGRA 400 plus test definition Hb

Abbreviated test name

HB-H3

Measuring mode

Absorbance

Abs. calculation mode

Endpoint

Reaction mode

R1-S

Reaction direction

Increase

Wavelength A/B

378/659 nm

Calc. first/last

17/33

Unit

mmol/L

Pipetting parameters

Hb

Diluent (H2O)

R1

120 µL

Sample

6 µL

0 µL

Total volume

126 µL

COBAS INTEGRA 400 plus test definition HbA1c

Abbreviated test name

A1-H3

Measuring mode

Absorbance

Abs. calculation mode

Endpoint

Reaction mode

R1-S-SR

Reaction direction

Increase

Wavelength A/B

340/659 nm

Calc. first/last

33/57

Unit

mmol/L

Pipetting parameters

HbA1c

Diluent (H2O)

R1

120 µL

Sample

6 µL

0 µL

SR

24 µL

0 µL

Total volume

150 µL

Ratio definition for mmol/mol HbA1c and % HbA1c calculation

Protocol 1 (mmol/mol HbA1c acc. to IFCC):

Abbreviated ratio name

RHI3 (0-621)

Equation

(A1-H3/HB-H3) × 1000

Unit

mM/M

Protocol 2 (% HbA1c acc. to DCCT/NGSP):

Abbreviated ratio name

RHD3 (0-622)

Equation

(A1-H3/HB-H3) × 91.5 + 2.15

Unit

%

Use the predefined profile (PA1H3, 0‑620) for simultaneous order entry of Hb (HB‑H3) and HbA1c (A1‑H3) tests from the same sample.

The ratio for HbA1c (mmol/mol HbA1c acc. to IFCC and % HbA1c acc. to DCCT/NGSP) will be automatically calculated after result output of both tests.

For dual reporting of both mmol/mol HbA1c (IFCC) units as well as % HbA1c (DCCT/NGSP) units please ensure that both ratio tests 0‑621 (acc. to IFCC) and 0‑620 (acc. to DCCT/NGSP) are activated.

", "Language": "en" }, { "Name": "StorageStability", "Value": "

Storage and stability

Reagent

Shelf life at 2‑8 °C

See expiration date on cobas c pack label

COBAS INTEGRA 400 plus system

On-board in use at 10‑15 °C

4 weeks

Reagent cannot be frozen.
If freezing of a cassette is suspected a control measurement with this cassette is recommended.

Hemolyzing reagent

Shelf life at 2‑8 °C

See expiration date on bottle label

COBAS INTEGRA 400 plus system

On-board in use, ISE rack, closed bottles

4 weeks

On-board in use, multi rack, open bottles

2 days

When storing at temperatures under 3 °C, the reagent may become cloudy. This has no effect on the function of the reagent and is reversible at higher temperatures. It is therefore recommended to equilibrate the reagent at room temperature for approximately 10 minutes and mix thoroughly before use.

", "Language": "en" }, { "Name": "Calibration", "Value": "

Calibration

Hb

Calibrator

C.f.a.s. HbA1c

HbA1c

Calibrator

C.f.a.s. HbA1c

Calibration dilution ratio

1:1, 1:1.5, 1:2.1, 1:3, 1:6, 1:15, performed automatically by the instrument

Calibrator diluent

COBAS INTEGRA Hemolyzing Reagent Gen.2, Cat. No. 04528328190

Calibration mode

Spline

Calibration replicate

Duplicate recommended

Calibration interval

Each lot, every 29 days, and as required following quality control procedures

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Traceability: This method has been standardized against the approved IFCC reference method for the measurement of HbA1c in human blood

LREFKobold U, Jeppsson JO, Duelffer T, et al. Candidate reference methods for hemoglobin A1c based on peptide mapping. Clin Chem 1997;43:1944-1951.
,
LREFJeppsson JO, Kobold U, Finke A, et al. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med 2002;40:78-89.
and can be transferred to results traceable to DCCT/NGSP by calculation.

Note

Enter the assigned lot-specific and application-specific value of the calibrator. Use the appropriate C.f.a.s. HbA1c calibrator only. COBAS INTEGRA Hemolyzing Reagent Gen.2, 6 × 11 mL, Cat. No. 04528328190, system‑ID 07 6851 0, needs to be available on the analyzer. Otherwise the calibration cannot be carried out.

", "Language": "en" }, { "Name": "Limitations", "Value": "", "Language": "en" }, { "Name": "PerformanceData", "Value": "

Specific performance data

Representative performance data on the COBAS INTEGRA analyzers are given below. Results obtained in individual laboratories may differ.

", "Language": "en" }, { "Name": "Precision", "Value": "

Precision

Repeatability and intermediate precision were determined using human samples and controls in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP5 requirements (2 aliquots per run, 2 runs per day, 21 days). The following results were obtained (data based on DCCT/NGSP values):

Repeatability

Mean
% HbA1c

SD
% HbA1c

CV
%

PreciControl HbA1c norm

5.88

0.10

1.8

PreciControl HbA1c path

10.6

0.07

0.7

Human sample 1

5.08

0.13

2.3

Human sample 2

6.51

0.13

2.0

Human sample 3

10.6

0.07

0.7

Human sample 4

7.57

0.08

1.1

Human sample 5

8.07

0.08

1.0

Intermediate precision

Mean
% HbA1c

SD
% HbA1c

CV
%

PreciControl HbA1c norm

5.88

0.12

2.0

PreciControl HbA1c path

10.6

0.11

1.0

Human sample 1

5.08

0.12

2.6

Human sample 2

6.51

0.14

2.1

Human sample 3

10.6

0.12

1.1

Human sample 4

7.57

0.11

1.4

Human sample 5

7.98

0.09

1.1

", "Language": "en" }, { "Name": "MethodComparison", "Value": "

Method comparison

Evaluation of method comparison data is according to former NGSP certification criteria. The mean difference between the two methods and the 95 % confidence intervals of the differences in the range from 4‑10 % (DCCT/NGSP) are given. 95 % of the differences between the values obtained for individual samples with both methods fall within the range defined by the lower and upper 95 % confidence intervals of the differences.

% HbA1c (DCCT/NGSP) values for human blood samples obtained on a COBAS INTEGRA 400 plus analyzer using the Tina‑quant Hemoglobin A1c Gen.3 reagent with the hemolysate application (y) were compared with those determined using the same reagent with the hemolysate application on a cobas c 501 analyzer (x).

Sample size (n) = 59

Mean difference: 0.16 % HbA1c

Lower 95 % confidence interval of differences: −0.14 % HbA1c

Upper 95 % confidence interval of differences: 0.45 % HbA1c

The sample concentrations were between 4.31 and 12.0 % HbA1c (DCCT/NGSP).

", "Language": "en" }, { "Name": "Summary", "Value": "

Summary

Summary

LREFGoldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care 1995;18:896-909.
,
LREFGoldstein DE, Little RR. More than you ever wanted to know (but need to know) about glycohemoglobin testing. Diabetes Care 1994;17:938-939.
,
LREFThe Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
,
LREFUK Prospective Diabetes Study (UKPDS) group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
,
LREFFinke A, Kobold U, Hoelzel W, et al. Preparation of a candidate primary reference material for the international standardization of HbA1c determinations. Clin Chem Lab Med 1998;36(5):299-308.
,
LREFGoldstein DE, Little RR, Wiedmeyer HM, et al. Glycated hemoglobin: methodologies and clinical applications. Clin Chem 1986;32:B64-B70.
,
LREFNathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008;31:1473-1478.
,
LREFBunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 1978;200:21-27.

Hemoglobin (Hb) consists of four protein subunits, each containing a heme moiety, and is the red-pigmented protein located in the erythrocytes. Its main function is to transport oxygen and carbon dioxide in blood. Each Hb molecule is able to bind four oxygen molecules. Hb consists of a variety of subfractions and derivatives. Among this heterogeneous group of hemoglobins HbA1c is one of the glycated hemoglobins, a subfraction formed by the attachment of various sugars to the Hb molecule. HbA1c is formed in two steps by the nonenzymatic reaction of glucose with the N‑terminal amino group of the β‑chain of normal adult Hb (HbA). The first step is reversible and yields labile HbA1c. This is rearranged to form stable HbA1c in a second reaction step.

In the erythrocytes, the relative amount of HbA converted to stable HbA1c increases with the average concentration of glucose in the blood. The conversion to stable HbA1c is limited by the erythrocyte’s life span of approximately 100 to 120 days. As a result, HbA1c reflects the average blood glucose level during the preceding 2 to 3 months. HbA1c is thus suitable to monitor long-term blood glucose control in individuals with diabetes mellitus. Glucose levels closer to the time of the assay have a greater influence on the HbA1c level.

LREFGoldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care 1995;18:896-909.

The approximate relationship between HbA1c and mean blood glucose values during the preceding 2 to 3 months was analyzed in several studies. A recent study obtained the following correlation:

IFCC standardization (recalculated acc. to ref. 8)

• Estimated average glucose [mmol/L] = 0.146 × HbA1c (mmol/mol) + 0.834

or

• Estimated average glucose [mg/dL] = 2.64 × HbA1c (mmol/mol) + 15.03

Standardization acc. to DCCT/NGSP

LREFGoldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care 1995;18:896-909.

• Estimated average glucose [mmol/L] = 1.59 × HbA1c (%) - 2.59

or

• Estimated average glucose [mg/dL] = 28.7 × HbA1c (%) - 46.7

The risk of diabetic complications, such as diabetic nephropathy and retinopathy, increases with poor metabolic control. In accordance with its function as an indicator for the mean blood glucose level, HbA1c predicts the development of diabetic complications in diabetes patients.

LREFThe Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
,
LREFUK Prospective Diabetes Study (UKPDS) group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.

For monitoring of long term glycemic control, testing every 3 to 4 months is generally sufficient. In certain clinical situations, such as gestational diabetes, or after a major change in therapy, it may be useful to measure HbA1c in 2 to 4 week intervals.

LREFGoldstein DE, Little RR, Wiedmeyer HM, et al. Glycated hemoglobin: methodologies and clinical applications. Clin Chem 1986;32:B64-B70.

", "Language": "en" }, { "Name": "Reagents", "Value": "

Reagents - working solutions

R1

Antibody reagent
MES

FREFMES = 2-morpholinoethane sulfonic acid
buffer: 0.025 mol/L; TRIS
FREFTRIS = Tris(hydroxymethyl)-aminomethane
buffer: 0.015 mol/L, pH 6.2; HbA1c antibody (ovine serum): ≥ 0.5 mg/mL; detergents; stabilizers; preservative

SR

Polyhapten reagent
MES buffer: 0.025 mol/L; TRIS buffer: 0.015 mol/L, pH 6.2; HbA1c polyhapten: ≥ 8 µg/mL; detergents; stabilizers; preservative

R1 is in position A and SR is in position C.

", "Language": "en" }, { "Name": "PrecautionsWarnings", "Value": "

Precautions and warnings

Pay attention to all precautions and warnings listed in Section 1 / Introduction of this Method Manual.

This kit contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:

2-methyl-2H-isothiazol-3-one hydrochloride

EUH 208

May produce an allergic reaction.

Product safety labeling follows EU GHS guidance.

", "Language": "en" }, { "Name": "Caution", "Value": "", "Language": "en" }, { "Name": "QualityControl", "Value": "

Quality control

Quality control

PreciControl HbA1c norm

PreciControl HbA1c path

Control interval

24 hours recommended

Control sequence

User defined

Control after calibration

Recommended

For quality control, use control materials as listed in the \"Order information\" section. In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory’s individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Note

Pretreat controls in the same way as samples.
HbA1c controls carry a declaration for mmol/mol HbA1c (IFCC) and % HbA1c (DCCT/NGSP) only. No declarations for Hb and HbA1c concentrations are provided. As a consequence, HbA1c controls are handled like samples and cannot be included in the COBAS INTEGRA systems Quality Control Program.

", "Language": "en" }, { "Name": "SpecimenPreparation", "Value": "

Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable.
Anticoagulated venous or capillary blood or hemolysate

The only acceptable anticoagulants are Li‑Heparin, K2‑EDTA, K3‑EDTA, Fluoride/Na2‑EDTA, Na‑Heparin and Fluoride/potassium oxalate.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

See the limitations and interferences section for details about possible sample interferences.

Stability:

3 days at 15‑25 °C

7 days at 2‑8 °C

6 months at (‑15)‑(‑25) °C

Freeze only once. Mix specimen thoroughly after thawing.

Manual hemolysate preparation

  1. Allow blood specimen and Hemolyzing Reagent for Tina‑quant HbA1c to equilibrate at room temperature before use.

  2. Moderately mix the sample immediately prior to pipetting, to ensure homogeneous mixture of erythrocytes. Take care to avoid the formation of foam.

  3. Dilute the sample with Hemolyzing Reagent for Tina‑quant HbA1c (Cat. No. 11488457122) in the ratio 1:101 (1+100) using one of the following pipetting schemes.

    Pipette into tubes:

    Hemolyzing Reagent for Tina‑quant HbA1c: 500 µL
    specimen (patient or control): 5 µL
    or
    Hemolyzing Reagent for Tina‑quant HbA1c: 1000 µL
    specimen (patient or control): 10 µL
    or
    Hemolyzing Reagent for Tina‑quant HbA1c: 2000 µL
    specimen (patient or control): 20 µL

  4. Mix using a vibration mixer or by gentle swirling.

  5. The hemolysate can be used after the solution has changed color from red to brownish-green (approximately 1‑2 min).

Stability of the hemolysate:

4 hours at 15‑25 °C

24 hours at 2‑8 °C

6 months at (‑15)‑(‑25) °C

", "Language": "en" } ] } } ] }

A1C-3

Tina-quant Hemoglobin A1c Gen.3

IVD For in vitro diagnostic use.
A1C-3

Overview

Detailed Specifications

Ordering Information

Compatible Instruments

...
    ...

    Technical Documents

    Access Material Data Sheets, Certificates of Analysis, and other product documentation.

    After clicking below, you will be redirected to eLabDoc, where you can choose your local country.
    error errorMessage
    Sorry, we couldn't find the content you are looking for
    Please try again later